[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Angiotech (Manan Medical Products, Inc.)\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":173},{"warningLetters":4,"total":172},[5,31,53,74,91,108,129,149],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},22101,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2026-11-03T05:00:00Z\">11\u002F03\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-08-19T04:00:00Z\">08\u002F19\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnext-medical-products-company-llc-727918-08192026\">Next Medical Products Company, LLC\u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Julia M. Jacobson\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Next Medical Products Company, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>45 Columbia Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Branchburg\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>08876\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6), (b)(7)(C)\"> (b)(6), (b)(7)(C)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS #727918\u003C\u002Fp>\u003Cp>August 19, 2026\u003C\u002Fp>\u003Cp>Dear Ms. Jacobson:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Branchburg, NJ from November 10, 2025 through December 10, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures Clear Image Ultrasound Gel, Clear Image Sterile, non-sterile MediChoice Ultrasound Gel, and Clear Image Singles. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820. We received responses from you dated January 2, 2026 and March 19, 2026 (responses), concerning our investigator observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to you on December 10, 2025. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to establish and maintain procedures where environmental conditions that could reasonably be expected to have an adverse effect on product quality, as required by 21 CFR 820.70(c). Specifically, “Quality Assurance Environmental Testing” procedure, Number 907-030, Revision 005 is not adequate in that:\u003C\u002Fp>\u003Cp>A. Section 2.0 of this procedure, which states “\u003Cstrong>(b)(4)\u003C\u002Fstrong> will be conducted \u003Cstrong>(b)(4)\u003C\u002Fstrong> on each packaging line. \u003Cstrong>(b)(4)\u003C\u002Fstrong>…” is not adequate. You have not demonstrated or justified why \u003Cstrong>(b)(4)\u003C\u002Fstrong> test result can be negated simply by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Further, your procedure does not require investigating failed test results nor does it address documenting a justification for the dismissal of the initial failed results. For example, your firm established environmental \u003Cstrong>(b)(4)\u003C\u002Fstrong> locations for Lots of Clear Image Ultrasound Gel that were packed in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Environmental sampling was performed by your firm on \u003Cstrong>(b)(4)\u003C\u002Fstrong> for \u003Cstrong>(b)(4)\u003C\u002Fstrong> for bottler dispense nozzle \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> dispensing nozzle \u003Cstrong>(b)(4)\u003C\u002Fstrong> and were recorded as out of specification for aerobic plate counts of 4,100 and 4,000 Colony Forming Units (CFUs) respectively. Your firm performed re-tests on \u003Cstrong>(b)(4)\u003C\u002Fstrong> that were in specification, but there was no documented justification for the dismissal of the initial data nor was any out of specification investigation performed.&nbsp;\u003C\u002Fp>\u003Cp>B. Your firm’s established worst case locations for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> locations listed in Section 2.0 of this procedure are not based on testing or data such as a bioburden\u003Cstrong>(b)(4)\u003C\u002Fstrong> study. You have not adequately demonstrated that the areas chosen are the worst case in terms of number or variety of organisms.\u003C\u002Fp>\u003Cp>C. Section 2.0 of this procedure, which states “The specified test regimen will be conducted \u003Cstrong>(b)(4)\u003C\u002Fstrong> unless findings are significant, in which case, Management may direct more frequent testing” is not adequate. It fails to define what constitutes significant findings. For example, your firm’s management did not consider directing more frequent testing after September 29, 2025, when the monitoring results for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> failed testing with a result of ≥25,000 CFUs.\u003C\u002Fp>\u003Cp>Your firm’s responses to 1A are not adequate. Your firm states in your responses that you will be implementing a correction to modify SOP 907-030 such that the use of environmental \u003Cstrong>(b)(4)\u003C\u002Fstrong> and air plates will only be triggered when and after the final microbial testing indicates that a lot is out of specification and will be used to trace the source of the problem. The requirements to establish environmental monitoring procedures are to ensure control of conditions, periodic inspection of control systems, and documentation and review of results. Only performing environmental \u003Cstrong>(b)(4)\u003C\u002Fstrong> and air plates testing after the final microbial testing fails is not adequate.\u003C\u002Fp>\u003Cp>Environmental control testing is crucial in non-sterile gel manufacturing to identify and prevent contamination by objectionable microorganisms, ensuring product safety, and efficacy. It validates that manufacturing environments (air, surfaces, water) are controlled to limit bioburden, preventing microbial degradation or toxins that could harm patients or damage the product's chemical properties.\u003C\u002Fp>\u003Cp>Your firm’s responses to 1B are not adequate. Your firm states the intent was to use the results of the recommended overly conservative sampling plan (worst case locations for environmental sample collection based on the opinion of consultants) and evaluate if this “test and adjust” methodology would have any effect on the finished product since its integrity and safety is assured by the final lot of microbial testing. There was no evidence provided in your responses that the areas chosen by the consultants were the worst case in terms of number or variety of organisms, and the corrective action provided in your responses of only performing environmental testing when the gel fails final lot microbial testing is not sufficient to detect all contaminants.\u003C\u002Fp>\u003Cp>Your firm’s responses to 1C is not adequate. Your firm states that “the fact that there was no change in the frequency of the testing does not indicate that the company failed to follow its own procedures or that such change would have been necessary”. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> monitoring results for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> had a failing result of &gt;25,000, which is orders of magnitude above your identified acceptable level provided in your Quality Assurance Environmental Testing procedure (Number 907-030 rev. 5, section 2) for Aerobic Plate Count (APC): \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your procedure does not clearly define “significant finding” and you do not justify why this failing result is not significant. This failing result is reasonably considered as a “significant finding” that needs to be investigated where your firm needs to identify the action(s) needed to correct and prevent recurrence of quality problems in the packaging area that can lead to contaminated ultrasound gel.\u003C\u002Fp>\u003Cp>2. Failure to establish procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). Specifically, your firm failed to adequately establish a Corrective and Preventive Action (CAPA) procedure that addresses all potential quality data sources for evaluation and escalation to CAPAs as needed. Although your “Corrective and Preventive Actions” Number 908-019, Revision 003 states under section 2.0 “any NEXT Medical employee may recommend a corrective or preventive action, or one may be initiated as a result of customer feedback, internal audits, directives from a regulatory agency, risk assessments, Management Review, supplier input, trends in nonconforming material and products, or any information that reveals an adverse effect on product quality and customer service”; it does not list all data sources that your firm is evaluating to determine the need for escalation to a CAPA. As a result, your firm is not initiating CAPAs to investigate the cause of nonconformities of product processes, and other quality problems. For example:\u003C\u002Fp>\u003Cp>A. Your firm documented a consecutive increase in out of specification aerobic plate count for environmental \u003Cstrong>(b)(4)\u003C\u002Fstrong> location taken from the dispense nozzle \u003Cstrong>(b)(4)\u003C\u002Fstrong> used for packaging of nonsterile Clear Image Ultrasound Gel in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The aerobic plate counts on sample date \u003Cstrong>(b)(4)\u003C\u002Fstrong> for \u003Cstrong>(b)(4)\u003C\u002Fstrong> failed for 4,000 Colony Forming Units (CFUs). Your firm performed re-tests on \u003Cstrong>(b)(4)\u003C\u002Fstrong> that were in specification but did not recommend corrective actions for the initial failure or after September 29, 2025 when the monitoring results for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> had another failing result of ≥25,000 CFUs. From the time period of August 27, 2025 to October 22, 2025, three lots (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) of Clear Image Ultrasonic gel were packaged in \u003Cstrong>(b)(4)\u003C\u002Fstrong> with \u003Cstrong>(b)(4)\u003C\u002Fstrong>, totaling \u003Cstrong>(b)(4)\u003C\u002Fstrong> cases. Corrective and preventive actions were not initiated.\u003C\u002Fp>\u003Cp>B. Procedure 907-030, revision 005 titled “Quality Assurance Environmental Testing” states in section 6.1.12 to “ship via overnight to \u003Cstrong>(b)(4)\u003C\u002Fstrong> for analysis” of the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. \u003Cstrong>(b)(4)\u003C\u002Fstrong> samples were collected on \u003Cstrong>(b)(4)\u003C\u002Fstrong> and were not sent to the lab until \u003Cstrong>(b)(4)\u003C\u002Fstrong>. These \u003Cstrong>(b)(4)\u003C\u002Fstrong> samples were tested on \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> and the bottler dispense nozzle \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and the \u003Cstrong>(b)(4)\u003C\u002Fstrong> dispensing nozzle \u003Cstrong>(b)(4)\u003C\u002Fstrong> samples failed for aerobic plate counts of 4,100 and 4,000 Colony Forming Units (CFUs). Although this incident was recorded in a note to file dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>, corrective and preventive actions were not initiated.\u003C\u002Fp>\u003Cp>Your firm’s responses to FDA-483 observation 2A are not adequate. Your firm states in your responses that the “out of specification results from the environmental testing did not reveal that the materials or finished product had been adversely affected or that it otherwise did not meet specifications”. Your firm has already released non-sterile ultrasound gel that did not meet specifications. Specifically, you have received complaints of unusual odor and cloudiness which you confirmed to be contaminated. In addition, your firm determined in your responses “that the provisions of Section 2 of SOP 908-019, Rev 003 were not applicable and no CAPA was required on that basis” due to an inadequate CAPA procedure. As already noted, your procedure does not adequately identify existing and potential causes of nonconformances in which to investigate, determine and implement corrective and preventive actions. Your firm failed to prevent the recurrence of the same quality issue when the aerobic plate counts on sample date \u003Cstrong>(b)(4)\u003C\u002Fstrong> for \u003Cstrong>(b)(4)\u003C\u002Fstrong> failed for 4,000 Colony Forming Units (CFUs) and then on September 29, 2025 the monitoring results for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> had another failing result of ≥25,000 CFUs.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response to 2B cannot be determined at this time. Your firm plans to update procedure SOP-019 to include process nonconformities as a quality data input for the determination of CAPAs in the future. This will include failure to ship laboratory samples within the designated \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>3. Failure to establish and maintain procedures for the identification, documentation, validation or where appropriate verification, review, and approval of design changes before their implementation, as required by 21 CFR 820.30(i). Specifically, your firm failed to implement “Product Development and Management of Design Changes” procedure, Number 500-004, section 7.1, which states “the process of making a significant change to an existing product involves a number of stages where information is managed in a very controlled environment consisting of inputs, outputs, verification processes and formal design reviews”. For example:\u003C\u002Fp>\u003Cp>A. Your firm introduced a new label insert (artwork \u003Cstrong>(b)(4)\u003C\u002Fstrong>, rev A) between \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> for your non-sterile gel that added contraindications and listed procedures requiring the use of sterile gel. Your firm characterized this as a marketing reminder processed through your label approval process rather than a design change that requires design verification or validation for the new label; \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches were produced with this insert. However, this change was made as a result of a safety concern connected to the non-sterile gel contamination issue reported by the Center for Disease Control (CDC).\u003C\u002Fp>\u003Cp>B. Your firm performed a design change on your Clear Image Ultrasound Scanning Gel in which a preservative ingredient was replaced and design verification and\u002For validation was not performed. This new preservative was a major formula change from \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong> (preservative and humectant enhancement). Your new preservative formula change adds a new specific effectiveness against paraburkholderia that was not part of the original formulation that could impact the performance, safety, and effectiveness of the ultrasound gel that would require design verification and\u002For validation before implementation.\u003C\u002Fp>\u003Cp>Your firm’s responses to 3A are not adequate. Your firm states in your response that “although we respectfully disagree with the proposition that the development of labeling materials (including advertising and promotional materials) necessarily constitute a change to a device’s specifications”. In your March 19 response, you included your revised Labels and Labeling Control procedure, SOP 703-001, and Section 2 states “All new or revised labeling shall be evaluated to determine whether the change impacts the device specifications. If the labeling change represents a modification to the device specifications, the change should be handled as a design change to the finished device.” This procedure is inadequate because it only considers a labeling change that impacts device specifications. Change control requirements apply to any change to the device, its labeling or its packaging. Additionally, your firm states in your responses that “NEXT respectfully disagrees with this observation as it appears to not be consistent with the facts as we understand them”. “The issuance of Artwork \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Rev A did not constitute a change to any “purchased, in-process or finished product” and was, instead an example of reminder labeling that did not add or delete any device contraindications or otherwise affect the device’s specifications”. This response is not adequate. Your firm characterized this as a marketing reminder rather than a design change conducted in response to a safety concern and did not evaluate the need for or conduct design verification or validation for the new label, processing it only through your label approval process.\u003C\u002Fp>\u003Cp>Your firm’s responses to 3B are not adequate. We acknowledge the additional testing you’re performing of the gel to verify it still meets specifications; however, your response is inadequate in that you have not demonstrated that the “change in preservative did not affect the gel’s mechanical properties or performance specifications”. The new preservative formula is a major formula change from \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong> which adds a new specific effectiveness against paraburkholderia that was not part of the original formulation that could impact the performance, safety, and effectiveness of the ultrasound gel that would require design verification and\u002For validation before implementation. Even though sterility may not be required, your firm must limit the number of organisms in the non-sterile Ultrasound gel throughout its shelf life.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Corrections and Removals Violation\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm’s Ultrasound Scanning Gel, distributed under the brand names Clear Image and MediChoice are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>Failure to submit a Report required by 21 CFR 806.10 to FDA, within 10 working days of initiating the correction or removal. For example: your firm found and CDC confirmed that certain lots of your Clear Image and MediChoice Ultrasound Scanning Gels were contaminated with Paraburkholderia. You sent customer letters and made calls using your firm’s telephone script on 07\u002F23\u002F2025, to inform customers and offer \"free replacement\" or \"disposal directions\". CDRH’s clinical review concludes that use of the contaminated gel may present a risk to health. This action is a medical device correction or removal initiated to reduce a risk to health posed by the device or to remedy a violation of the Act caused by the device which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA. As of 12\u002F10\u002F2025, you did not submit a Medical Device Report of Correction or Removal to FDA for this action.\u003C\u002Fp>\u003Cp>Your firm’s responses are not adequate. You have not submitted a Report of Correction or Removal to FDA as of August 13, 2026.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved Device Violation\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection also revealed that the Ultrasound Scanning Gel, distributed under the brand names Clear Image and MediChoice, is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The device is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)] The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\u003Cp>Specifically, the Clear Image Ultrasound Scanning Gel was cleared under K883917 as a coupling agent during ultrasound procedures to eliminate air between transducer surface and skin to facilitate imaging. Your firm changed the preservative in the subject ultrasound gel formulation from \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong> in 2024, which is considered a modification in material formulation that could significantly affect the device's safety or effectiveness. These changes thus require a 510(k) as provided in 21 CFR 807.81(a)(3)(i).\u003C\u002Fp>\u003Cp>The change could affect the device’s biocompatibility, stability, sterility and shelf life. As described here, the new preservative, \u003Cstrong>(b)(4)\u003C\u002Fstrong> (which contains \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>), represents a change in the chemical profile compared to \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and therefore the biocompatibility must be re-evaluated. Your firm must ensure that the new preservative maintains the same preservative effectiveness, stability, sterility and shelf-life claims as previously cleared. The repeat biocompatibility testing, preservative effectiveness, shelf life, and stability should be reviewed in a new 510(k) by the Agency. The firm must demonstrate that the number of organisms in the subject ultrasound gel is limited throughout its shelf life.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>On February 2, 2024, the FDA issued a \u003Cu>final rule\u003C\u002Fu> amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. Your most recent inspection on November 10, 2025, through December 10, 2025 was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, any corrective actions you propose or implement must be pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Establishment Assessment Team 1 Assistant Director Gina Brackett at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 727918” when replying. If you have any questions about the contents of this letter, please contact: Robert Maffei, Compliance Officer at Robert.Maffei@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Barbara C. Marsden\u003Cbr>Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMs. Julia M. Jacobson\n\nRecipient Title\n\nPresident and CEO\n\nNext Medical Products Company, LLC\n\n45 Columbia Road\n\nBranchburg, NJ 08876\n\nUnited States\n\n(b)(6), (b)(7)(C)\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS #727918\nAugust 19, 2026\nDear Ms. Jacobson:\nDuring an inspection of your firm located in Branchburg, NJ from November 10, 2025 through December 10, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures Clear Image Ultrasound Gel, Clear Image Sterile, non-sterile MediChoice Ultrasound Gel, and Clear Image Singles. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nQuality System Regulation Violations\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received responses from you dated January 2, 2026 and March 19, 2026 (responses), concerning our investigator observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to you on December 10, 2025. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to establish and maintain procedures where environmental conditions that could reasonably be expected to have an adverse effect on product quality, as required by 21 CFR 820.70(c). Specifically, “Quality Assurance Environmental Testing” procedure, Number 907-030, Revision 005 is not adequate in that:\nA. Section 2.0 of this procedure, which states “(b)(4) will be conducted (b)(4) on each packaging line. (b)(4)…” is not adequate. You have not demonstrated or justified why (b)(4) test result can be negated simply by (b)(4). Further, your procedure does not require investigating failed test results nor does it address documenting a justification for the dismissal of the initial failed results. For example, your firm established environmental (b)(4) locations for Lots of Clear Image Ultrasound Gel that were packed in (b)(4). Environmental sampling was performed by your firm on (b)(4) for (b)(4) for bottler dispense nozzle (b)(4) and (b)(4) dispensing nozzle (b)(4) and were recorded as out of specification for aerobic plate counts of 4,100 and 4,000 Colony Forming Units (CFUs) respectively. Your firm performed re-tests on (b)(4) that were in specification, but there was no documented justification for the dismissal of the initial data nor was any out of specification investigation performed.\nB. Your firm’s established worst case locations for the (b)(4) locations listed in Section 2.0 of this procedure are not based on testing or data such as a bioburden(b)(4) study. You have not adequately demonstrated that the areas chosen are the worst case in terms of number or variety of organisms.\nC. Section 2.0 of this procedure, which states “The specified test regimen will be conducted (b)(4) unless findings are significant, in which case, Management may direct more frequent testing” is not adequate. It fails to define what constitutes significant findings. For example, your firm’s management did not consider directing more frequent testing after September 29, 2025, when the monitoring results for the (b)(4) failed testing with a result of ≥25,000 CFUs.\nYour firm’s responses to 1A are not adequate. Your firm states in your responses that you will be implementing a correction to modify SOP 907-030 such that the use of environmental (b)(4) and air plates will only be triggered when and after the final microbial testing indicates that a lot is out of specification and will be used to trace the source of the problem. The requirements to establish environmental monitoring procedures are to ensure control of conditions, periodic inspection of control systems, and documentation and review of results. Only performing environmental (b)(4) and air plates testing after the final microbial testing fails is not adequate.\nEnvironmental control testing is crucial in non-sterile gel manufacturing to identify and prevent contamination by objectionable microorganisms, ensuring product safety, and efficacy. It validates that manufacturing environments (air, surfaces, water) are controlled to limit bioburden, preventing microbial degradation or toxins that could harm patients or damage the product's chemical properties.\nYour firm’s responses to 1B are not adequate. Your firm states the intent was to use the results of the recommended overly conservative sampling plan (worst case locations for environmental sample collection based on the opinion of consultants) and evaluate if this “test and adjust” methodology would have any effect on the finished product since its integrity and safety is assured by the final lot of microbial testing. There was no evidence provided in your responses that the areas chosen by the consultants were the worst case in terms of number or variety of organisms, and the corrective action provided in your responses of only performing environmental testing when the gel fails final lot microbial testing is not sufficient to detect all contaminants.\nYour firm’s responses to 1C is not adequate. Your firm states that “the fact that there was no change in the frequency of the testing does not indicate that the company failed to follow its own procedures or that such change would have been necessary”. The (b)(4) monitoring results for the (b)(4) had a failing result of >25,000, which is orders of magnitude above your identified acceptable level provided in your Quality Assurance Environmental Testing procedure (Number 907-030 rev. 5, section 2) for Aerobic Plate Count (APC): (b)(4). Your procedure does not clearly define “significant finding” and you do not justify why this failing result is not significant. This failing result is reasonably considered as a “significant finding” that needs to be investigated where your firm needs to identify the action(s) needed to correct and prevent recurrence of quality problems in the packaging area that can lead to contaminated ultrasound gel.\n2. Failure to establish procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). Specifically, your firm failed to adequately establish a Corrective and Preventive Action (CAPA) procedure that addresses all potential quality data sources for evaluation and escalation to CAPAs as needed. Although your “Corrective and Preventive Actions” Number 908-019, Revision 003 states under section 2.0 “any NEXT Medical employee may recommend a corrective or preventive action, or one may be initiated as a result of customer feedback, internal audits, directives from a regulatory agency, risk assessments, Management Review, supplier input, trends in nonconforming material and products, or any information that reveals an adverse effect on product quality and customer service”; it does not list all data sources that your firm is evaluating to determine the need for escalation to a CAPA. As a result, your firm is not initiating CAPAs to investigate the cause of nonconformities of product processes, and other quality problems. For example:\nA. Your firm documented a consecutive increase in out of specification aerobic plate count for environmental (b)(4) location taken from the dispense nozzle (b)(4) used for packaging of nonsterile Clear Image Ultrasound Gel in (b)(4). The aerobic plate counts on sample date (b)(4) for (b)(4) failed for 4,000 Colony Forming Units (CFUs). Your firm performed re-tests on (b)(4) that were in specification but did not recommend corrective actions for the initial failure or after September 29, 2025 when the monitoring results for the (b)(4) had another failing result of ≥25,000 CFUs. From the time period of August 27, 2025 to October 22, 2025, three lots ((b)(4)) of Clear Image Ultrasonic gel were packaged in (b)(4) with (b)(4), totaling (b)(4) cases. Corrective and preventive actions were not initiated.\nB. Procedure 907-030, revision 005 titled “Quality Assurance Environmental Testing” states in section 6.1.12 to “ship via overnight to (b)(4) for analysis” of the (b)(4). (b)(4) samples were collected on (b)(4) and were not sent to the lab until (b)(4). These (b)(4) samples were tested on (b)(4) and (b)(4) and the bottler dispense nozzle (b)(4), and the (b)(4) dispensing nozzle (b)(4) samples failed for aerobic plate counts of 4,100 and 4,000 Colony Forming Units (CFUs). Although this incident was recorded in a note to file dated (b)(4), corrective and preventive actions were not initiated.\nYour firm’s responses to FDA-483 observation 2A are not adequate. Your firm states in your responses that the “out of specification results from the environmental testing did not reveal that the materials or finished product had been adversely affected or that it otherwise did not meet specifications”. Your firm has already released non-sterile ultrasound gel that did not meet specifications. Specifically, you have received complaints of unusual odor and cloudiness which you confirmed to be contaminated. In addition, your firm determined in your responses “that the provisions of Section 2 of SOP 908-019, Rev 003 were not applicable and no CAPA was required on that basis” due to an inadequate CAPA procedure. As already noted, your procedure does not adequately identify existing and potential causes of nonconformances in which to investigate, determine and implement corrective and preventive actions. Your firm failed to prevent the recurrence of the same quality issue when the aerobic plate counts on sample date (b)(4) for (b)(4) failed for 4,000 Colony Forming Units (CFUs) and then on September 29, 2025 the monitoring results for the (b)(4) had another failing result of ≥25,000 CFUs.\nThe adequacy of your firm’s response to 2B cannot be determined at this time. Your firm plans to update procedure SOP-019 to include process nonconformities as a quality data input for the determination of CAPAs in the future. This will include failure to ship laboratory samples within the designated (b)(4).\n3. Failure to establish and maintain procedures for the identification, documentation, validation or where appropriate verification, review, and approval of design changes before their implementation, as required by 21 CFR 820.30(i). Specifically, your firm failed to implement “Product Development and Management of Design Changes” procedure, Number 500-004, section 7.1, which states “the process of making a significant change to an existing product involves a number of stages where information is managed in a very controlled environment consisting of inputs, outputs, verification processes and formal design reviews”. For example:\nA. Your firm introduced a new label insert (artwork (b)(4), rev A) between (b)(4) and (b)(4) for your non-sterile gel that added contraindications and listed procedures requiring the use of sterile gel. Your firm characterized this as a marketing reminder processed through your label approval process rather than a design change that requires design verification or validation for the new label; (b)(4) batches were produced with this insert. However, this change was made as a result of a safety concern connected to the non-sterile gel contamination issue reported by the Center for Disease Control (CDC).\nB. Your firm performed a design change on your Clear Image Ultrasound Scanning Gel in which a preservative ingredient was replaced and design verification and\u002For validation was not performed. This new preservative was a major formula change from (b)(4) to (b)(4) (preservative and humectant enhancement). Your new preservative formula change adds a new specific effectiveness against paraburkholderia that was not part of the original formulation that could impact the performance, safety, and effectiveness of the ultrasound gel that would require design verification and\u002For validation before implementation.\nYour firm’s responses to 3A are not adequate. Your firm states in your response that “although we respectfully disagree with the proposition that the development of labeling materials (including advertising and promotional materials) necessarily constitute a change to a device’s specifications”. In your March 19 response, you included your revised Labels and Labeling Control procedure, SOP 703-001, and Section 2 states “All new or revised labeling shall be evaluated to determine whether the change impacts the device specifications. If the labeling change represents a modification to the device specifications, the change should be handled as a design change to the finished device.” This procedure is inadequate because it only considers a labeling change that impacts device specifications. Change control requirements apply to any change to the device, its labeling or its packaging. Additionally, your firm states in your responses that “NEXT respectfully disagrees with this observation as it appears to not be consistent with the facts as we understand them”. “The issuance of Artwork (b)(4), Rev A did not constitute a change to any “purchased, in-process or finished product” and was, instead an example of reminder labeling that did not add or delete any device contraindications or otherwise affect the device’s specifications”. This response is not adequate. Your firm characterized this as a marketing reminder rather than a design change conducted in response to a safety concern and did not evaluate the need for or conduct design verification or validation for the new label, processing it only through your label approval process.\nYour firm’s responses to 3B are not adequate. We acknowledge the additional testing you’re performing of the gel to verify it still meets specifications; however, your response is inadequate in that you have not demonstrated that the “change in preservative did not affect the gel’s mechanical properties or performance specifications”. The new preservative formula is a major formula change from (b)(4) to (b)(4) which adds a new specific effectiveness against paraburkholderia that was not part of the original formulation that could impact the performance, safety, and effectiveness of the ultrasound gel that would require design verification and\u002For validation before implementation. Even though sterility may not be required, your firm must limit the number of organisms in the non-sterile Ultrasound gel throughout its shelf life.\nCorrections and Removals Violation\nOur inspection also revealed that your firm’s Ultrasound Scanning Gel, distributed under the brand names Clear Image and MediChoice are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\nFailure to submit a Report required by 21 CFR 806.10 to FDA, within 10 working days of initiating the correction or removal. For example: your firm found and CDC confirmed that certain lots of your Clear Image and MediChoice Ultrasound Scanning Gels were contaminated with Paraburkholderia. You sent customer letters and made calls using your firm’s telephone script on 07\u002F23\u002F2025, to inform customers and offer \"free replacement\" or \"disposal directions\". CDRH’s clinical review concludes that use of the contaminated gel may present a risk to health. This action is a medical device correction or removal initiated to reduce a risk to health posed by the device or to remedy a violation of the Act caused by the device which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA. As of 12\u002F10\u002F2025, you did not submit a Medical Device Report of Correction or Removal to FDA for this action.\nYour firm’s responses are not adequate. You have not submitted a Report of Correction or Removal to FDA as of August 13, 2026.\nUnapproved Device Violation\nOur inspection also revealed that the Ultrasound Scanning Gel, distributed under the brand names Clear Image and MediChoice, is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The device is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)] The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\nSpecifically, the Clear Image Ultrasound Scanning Gel was cleared under K883917 as a coupling agent during ultrasound procedures to eliminate air between transducer surface and skin to facilitate imaging. Your firm changed the preservative in the subject ultrasound gel formulation from (b)(4) to (b)(4) in 2024, which is considered a modification in material formulation that could significantly affect the device's safety or effectiveness. These changes thus require a 510(k) as provided in 21 CFR 807.81(a)(3)(i).\nThe change could affect the device’s biocompatibility, stability, sterility and shelf life. As described here, the new preservative, (b)(4) (which contains (b)(4) and (b)(4)), represents a change in the chemical profile compared to (b)(4), and therefore the biocompatibility must be re-evaluated. Your firm must ensure that the new preservative maintains the same preservative effectiveness, stability, sterility and shelf-life claims as previously cleared. The repeat biocompatibility testing, preservative effectiveness, shelf life, and stability should be reviewed in a new 510(k) by the Agency. The firm must demonstrate that the number of organisms in the subject ultrasound gel is limited throughout its shelf life.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nOn February 2, 2024, the FDA issued a final rule amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. Your most recent inspection on November 10, 2025, through December 10, 2025 was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, any corrective actions you propose or implement must be pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Establishment Assessment Team 1 Assistant Director Gina Brackett at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 727918” when replying. If you have any questions about the contents of this letter, please contact: Robert Maffei, Compliance Officer at Robert.Maffei@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nBarbara C. Marsden\nDirector\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","Next Medical Products Company, LLC","next-medical-products-company-llc-727918-08192026","2026-11-10T01:02:16.121874+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnext-medical-products-company-llc-727918-08192026","2026-11-17T01:02:03.701861+00:00","Warning Letter","Issued","2026-11-03","727918","Medical Devices","Ms. Julia M. Jacobson","2026-11-10T01:03:13.668+00:00","VIA Electronic Mail","2026-08-19",{"id":32,"raw":33,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":23,"posted_date":46,"marcs_cms_no":47,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":49,"body_fetched_at":50,"delivery_method":51,"recipient_title":19,"reference_number":19,"action_taken_date":52,"medical_device_id":19,"response_letter_date":19},234,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2026-04-14T04:00:00Z\">04\u002F14\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-04-09T04:00:00Z\">04\u002F09\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedical-products-laboratories-inc-721916-04092026\">Medical Products Laboratories, Inc.\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u002FUnapproved New Drug","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Elliot Stone\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u002FCEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Medical Products Laboratories, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>9990 Global Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Philadelphia\u003C\u002Fspan>, \u003Cspan>PA\u003C\u002Fspan> \u003Cspan>19115\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-61\u003C\u002Fp>\u003Cp>April 9, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Stone:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Medical Products Laboratories, Inc., FEI 2513595, at 9990 Global Road, Philadelphia, from September 29 to October 16, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>Your firm manufactures and is responsible for introducing or delivering for introduction into interstate commerce in the United States products that are unapproved new drugs in violation of sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. Sections 331(d) and 355(a), including but not limited to: Hydro-Q 4% Gel (hydroquinone 4%); Sodium Sulfacetamide 8% and Sulfur 4% Topical Suspension; Sodium Sulfacetamide 9% and Sulfur 4% Wash; Sodium Sulfacetamide 9.8% Shampoo; Sodium Sulfacetamide 9.8% and Sulfur 4.8% Cleanser; Sodium Sulfacetamide 9.8% and Sulfur 4.8% Lotion; Sodium Sulfacetamide 9.8% and Sulfur 4.8% Cream; Sodium Sulfacetamide 10% and Sulfur 5% Cleanser; Sodium Sulfacetamide 10% Wash; Salicylic Acid 28.5% Solution; Plexion Shampoo (sodium sulfacetamide 9.8%); Plexion Lotion (sodium sulfacetamide 9.8% and sulfur 4.8%), Plexion Cream (sodium sulfacetamide 9.8% and sulfur 4.8%) as prescription drug products. Based on our review, these products are unapproved new drugs under section 505(a) of the FD&amp;C Act, 21 U.S.C. Section 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. Sections 331(d) and 355(a).\u003C\u002Fp>\u003Cp>We reviewed your November 6, 2025 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to establish and follow appropriate written procedures, designed to prevent objectionable microorganisms in drug products not required to be sterile (21 CFR 211.113(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Microbiological Results in Finished Drug Product and \u003Cstrong>(b)(4)\u003C\u002Fstrong> Samples\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your firm manufactures prescription and over-the-counter (OTC) drug products for \u003Cstrong>(b)(4)\u003C\u002Fstrong> administration. You failed to adequately establish and follow procedures to prevent contamination with objectionable microorganisms. For example, you used an unvalidated \u003Cstrong>(b)(4)\u003C\u002Fstrong> treatment protocol on filled drug product batches in an attempt to reduce microbiological content. Your laboratory reported gross microbiological contamination on plates for both total aerobic microbiological count (TAMC) and total yeast and mold count (TYMC) tests in the following non-sterile finished drug products for \u003Cstrong>(b)(4)\u003C\u002Fstrong> administration:\u003C\u002Fp>\u003Cul>\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> (TAMC: too numerous to count (TNTC) and TYMC: TNTC)\u003C\u002Fli>\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> (TAMC: TNTC and TYMC: TNTC)\u003C\u002Fli>\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> (TAMC: TNTC and TYMC: \u003Cstrong>(b)(4)\u003C\u002Fstrong> colony forming units (CFU) per gram)\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your investigation of the failing results in \u003Cstrong>(b)(4)\u003C\u002Fstrong> lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> concluded that contamination was from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> component, recovered from a mixture of this component with \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, your investigation failed to consider out-of-limit (OOL) microbiological recoveries from your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system.\u003C\u002Fp>\u003Cp>You subsequently released drug products based on results from \u003Cstrong>(b)(4)\u003C\u002Fstrong> treatment resampling. Your corrective action and preventive action (CAPA) in response to the microbiological contamination included revising the drug product formulation to increase \u003Cstrong>(b)(4)\u003C\u002Fstrong> content. \u003Cstrong>(b)(4)\u003C\u002Fstrong> are not a substitute for a comprehensive approach to preventing objectionable microorganisms from contaminating your drug products and cannot be relied on to reduce in-process bioburden during manufacturing.\u003C\u002Fp>\u003Cp>We note that on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you issued a voluntary recall of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, lots \u003Cstrong>(b)(4)\u003C\u002Fstrong>, due to microbiological contamination.\u003C\u002Fp>\u003Cp>Your response commits to revising your procedures to no longer allow \u003Cstrong>(b)(4)\u003C\u002Fstrong> treatment to rework batches after failing microbiological results and to place a reworked batch on real-time stability. You also include a risk assessment which concludes there is no health risk for two failing lots. Your response is inadequate in that your risk assessment does not extend to all drug products where \u003Cstrong>(b)(4)\u003C\u002Fstrong> treatment was attempted, nor does your response provide your plans for addressing product quality and patient safety risks for lots on which you used \u003Cstrong>(b)(4)\u003C\u002Fstrong> treatment or product you released after failing microbiological results. Moreover, your response does not address whether additional bacterial species were present, nor did you provide evidence supporting your claims that growth on total yeast and mold plates was solely bacterial.\u003C\u002Fp>\u003Cp>This adverse pattern of microbiological contamination in your drug products demonstrates a significant failure to adhere to CGMP. Unresolved manufacturing and quality problems can pose a significant hazard to patients.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment of the design and control of your firm’s manufacturing operations, with a detailed and thorough review of all microbiological hazards.\u003C\u002Fli>\u003Cli>A detailed risk assessment addressing the hazards posed by distributing drug products with potentially objectionable contamination. Specify actions you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fli>\u003Cli>Complete investigations into all batches with potential objectionable microbiological contamination or a failing microbiological result (whether or not later invalidated). The investigations should detail your findings regarding the root causes of the contamination.\u003C\u002Fli>\u003Cli>Appropriate microbiological batch release specifications (i.e., total counts, identification of bioburden to detect objectionable microbes) for each of your drug products.\u003C\u002Fli>\u003Cli>A summary of results from testing retain samples of all drug product batches of which you have received failing, out-of-specification (OOS), OOL or out-of-trend (OOT) microbiological test results. Also provide test results of retains during periods when your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system was not operating under a state of control. You should test microbiological quality (total counts and identification of bioburden to detect any objectionable microbes) of each batch. If testing yields any failing, OOS or OOL result, indicate the corrective actions you will take, including notifying customers and initiating recalls.\u003C\u002Fli>\u003Cli>A comprehensive remediation plan for the design, control, and maintenance of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> system.\u003Cbr>o Provide a comprehensive evaluation of vulnerabilities of \u003Cstrong>(b)(4)\u003C\u002Fstrong> system design and control, and summarize all deficiencies found in the system. The summary should, at minimum, describe various system characteristics that were assessed for adequacy (system temperature, materials of construction, slope, any identified dead-legs, any stagnant locations, any unsanitary fittings, flow velocity, etc.)\u003C\u002Fli>\u003Cli>Your total microbiological count limits to monitor whether this system is producing \u003Cstrong>(b)(4)\u003C\u002Fstrong> suitable for the intended uses for each of your products.\u003C\u002Fli>\u003Cli>A detailed risk assessment addressing the potential effects of the observed \u003Cstrong>(b)(4)\u003C\u002Fstrong> system failures on the quality of all drug product lots currently within expiry. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to adequately validate your manufacturing processes to demonstrate that your processes are reproducible and controlled to consistently yield drug products of uniform character and quality. For example, you used a process qualification study performed at a different facility to manufacture and release \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You could not provide evidence your processes (e.g. equipment, components, and manufacturing conditions) were comparable between your facility and the site where initial process validation was performed.\u003C\u002Fp>\u003Cp>Additionally, you failed to adequately validate your process for manufacturing \u003Cstrong>(b)(4)\u003C\u002Fstrong>. While a process validation study for this product had been initiated, it included insufficient data. At the direction of your customer, you discontinued your efforts to complete process validation for this product, yet you continued manufacturing batches for commercial distribution.\u003C\u002Fp>\u003Cp>In your response, you discuss a retrospective review of \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches within expiry. You also indicate that you have paused production of \u003Cstrong>(b)(4)\u003C\u002Fstrong> until process validation activities can be completed. You also state that you have updated your process validation procedure and that you have verified that process validation studies have been conducted for drug products you manufacture. Your response is inadequate in that you did not evaluate the implications of changes made to product formulations for drug products that you manufacture.\u003C\u002Fp>\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\u003C\u002Fp>\u003Cp>Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003C\u002Fli>\u003Cli>A timeline for performing appropriate PPQ for each of your marketed drug products which lack appropriate studies. Also include an explanation how you will ensure proper satisfactory PPQ studies are performed prior to future distribution of any drug products.\u003C\u002Fli>\u003Cli>A risk assessment for the distributed drug products produced without performing any process validation studies or using inadequately validated processes.\u003C\u002Fli>\u003Cli>Process performance protocol(s), and written procedures for qualification of equipment and facilities.\u003C\u002Fli>\u003Cli>A detailed program, including your procedure, for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Finished Drug Product Microbiological Testing\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your firm failed to adequately investigate failing microbiological results in finished products. For example, your \u003Cstrong>(b)(4)\u003C\u002Fstrong> lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> obtained a failing result of \u003Cstrong>(b)(4)\u003C\u002Fstrong> CFU\u002Fg for TYMC (specification ≤\u003Cstrong>(b)(4)\u003C\u002Fstrong> CFU\u002Fg). After your contract testing laboratory failed to identify the fungal species, you concluded, without evidence, that contamination occurred “during handling, transportation and\u002For testing.” You invalidated this failing result based on results of resampling and released the lot.\u003C\u002Fp>\u003Cp>Microbiological contamination may not be uniformly distributed. A product sample may not be representative of the type or level of contamination within the batch. Further, testing the final product for microbiological contamination does not ensure that you have appropriate controls in place to ensure product quality. As a manufacturer, you have a responsibility to fully investigate unexplained discrepancies, deviations, and failures to assess their impact on product quality.\u003C\u002Fp>\u003Cp>\u003Cem>Stability Assay\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your firm failed to conduct adequate investigations into OOS stability results. For example, in two separate incidents, you invalidated OOS stability results for subpotent assay without adequate scientific justification. You relied on resampling data from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, lots \u003Cstrong>(b)(4)\u003C\u002Fstrong>, to invalidate the initial stability OOS result with no identified laboratory error or rationale.\u003C\u002Fp>\u003Cp>\u003Cem>Complaint Investigations\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You did not adequately investigate complaints you received. For example, upon receiving complaints of product crystallization in \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you concluded that this crystallization was due to “transportation and\u002For storage” during winter months. Your investigation failed to consider changes made to the formulation or the status of process validation activities for the formulation.\u003C\u002Fp>\u003Cp>In your response, you commit to reopening complaints of crystallization and discoloration of \u003Cstrong>(b)(4)\u003C\u002Fstrong> while pausing manufacturing of this product. You also commit to revising your complaint and investigation procedures, but you did not provide revised procedures. Your response also fails to perform a retrospective review of invalidated OOS results or discuss improperly invalidated results for drug products which remain on the market.\u003C\u002Fp>\u003Cp>Inadequate investigations can lead to unidentified root causes, ineffective CAPA, and recurring problems that compromise the ability to manufacture safe and effective drug products.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\u003Cli>A retrospective, independent review of all invalidated failing\u002FOOS (including in-process and release\u002Fstability testing) results for U.S. products currently in the U.S. market and within expiry as of the date of this letter and a report summarizing the findings of the analysis, including the following for each OOS:\u003Cbr>o Determine whether the scientific justification and evidence relating to the invalidated failing\u002FOOS results conclusively or inconclusively demonstrates causative laboratory error.\u003Cbr>o For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\u003Cbr>o For all failing\u002FOOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\u003C\u002Fli>\u003Cli>A comprehensive review and remediation plan for your failing\u002FOOS result investigation systems. The CAPA should include but not be limited to addressing the following:\u003Cbr>o Quality unit oversight of laboratory investigations\u003Cbr>o Identification of adverse laboratory control trends\u003Cbr>o Resolution of causes of laboratory variation\u003Cbr>o Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\u003Cbr>o Adequately scoping of each investigation and its CAPA\u003Cbr>o Revised failing\u002FOOS investigation procedures with these and other remediations\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>4. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your stability program was not adequate to ensure that the drug products you manufacture, maintain their identity, strength, quality, purity, and safety throughout their shelf lives. For example, your stability study for \u003Cstrong>(b)(4)\u003C\u002Fstrong> concluded that a \u003Cstrong>(b)(4)\u003C\u002Fstrong> expiration is supported at a temperature of \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong> degrees Celsius (\u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong> degrees Fahrenheit). However, your firm labeled much wider storage conditions as \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong> degrees Fahrenheit at the instruction of your customer, without adequate data to support the wider labeled storage conditions. We note that you reduced the range of the labeled temperature limits, but they were still outside the range of your stability data.\u003C\u002Fp>\u003Cp>In your response, you committed to revising the stability protocol for this product and placing future lots on stability. You also state that you “can no longer rely on written justifications from product owners to deviate from the general [C]GMP requirements.” Your response is inadequate in that you do not include a comprehensive review of your stability program, nor do you provide your revised stability protocol. Additionally, your response does not describe a retrospective review of batches which lack adequate stability data to support labeled expiration dates and storage conditions.\u003C\u002Fp>\u003Cp>Without the appropriate stability studies, you do not have adequate scientific evidence to support that your drug product retains its quality attributes throughout the labeled \u003Cstrong>(b)(4)\u003C\u002Fstrong> expiry period.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003Cbr>o Stability indicating methods\u003Cbr>o Stability studies for each drug product in its marketed container-closure system before distribution is permitted\u003Cbr>o An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\u003Cbr>o A detailed definition of the specific attributes to be tested at each station (timepoint)\u003Cbr>o All procedures that describe these and other elements of your remediated stability program.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm’s products are drugs as defined by section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. Section 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For intended to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Examples from your product labeling that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>Hydro-Q Gel (hydroquinone 4%)\u003C\u002Fp>\u003Cul>\u003Cli>Indicated for the gradual bleaching of hyperpigmented skin conditions such as chloasma, melasma, freckles, senile lentigines and areas of melanin hyperpigmentation.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Plexion Shampoo (sodium sulfacetamide 9.8%)\u003C\u002Fp>\u003Cul>\u003Cli>Intended for topical application in the following scaling dermatoses: seborrheic dermatitis and seborrhea sicca (dandruff).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Plexion Cream and Plexion Lotion (sodium sulfacetamide 9.8%, sulfur 4.8%)\u003C\u002Fp>\u003Cul>\u003Cli>Indicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Sodium Sulfacetamide 9.8% Shampoo\u003C\u002Fp>\u003Cul>\u003Cli>Intended for topical application in the following scaling dermatoses: seborrheic dermatitis and seborrhea sicca (dandruff).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Sodium Sulfacetamide 10% Wash\u003C\u002Fp>\u003Cul>\u003Cli>Indicated for topical application in the following scaling dermatoses: seborrheic dermatitis and seborrhea sicca (dandruff). It also is indicated for the treatment of secondary bacterial infections of the skin due to organisms susceptible to sulfonamides.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Sodium Sulfacetamide 9.8% and Sulfur 4.8% Cream, Cleanser, and Lotion\u003C\u002Fp>\u003Cul>\u003Cli>Indicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Sodium Sulfacetamide 8% and Sulfur 4% Topical Suspension\u003C\u002Fp>\u003Cul>\u003Cli>Indicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Sodium Sulfacetamide 9% and Sulfur 4% Wash\u003C\u002Fp>\u003Cul>\u003Cli>Indicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Sodium Sulfacetamide 10% and Sulfur 5% Cleanser\u003C\u002Fp>\u003Cul>\u003Cli>Indicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Salicylic Acid 28.5% Solution\u003C\u002Fp>\u003Cul>\u003Cli>Indicated for the topical treatment and removal of common warts and plantar warts.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your products are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the above-described conditions prescribed, recommended, or suggested in their labeling.\u003C\u002Fp>\u003Cp>With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for these products.\u003C\u002Fp>\u003Cp>Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Responsibilities as a Contractor\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\u003C\u002Fp>\u003Cp>You and your customer \u003Cstrong>(b)(4)\u003C\u002Fstrong>, have a quality agreement regarding the manufacture of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>Quality Systems\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm’s quality systems are inadequate. For guidance on establishing and maintaining CGMP-compliant quality systems, see FDA’s guidances: \u003Cem>Q8(R2) Pharmaceutical Development\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71535\u002Fdownload, \u003Cem>Q9(R1) Quality Risk Management\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167721\u002Fdownload and \u003Cem>Q10 Pharmaceutical Quality System\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71553\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>FDA requests that you contact CDER's Drug Shortages Staff immediately at drugshortages@fda.hhs.gov so that we can work with you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture, as required under 21 U.S.C.§ 356c(a), and to allow FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who use your products.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 2513595 and ATTN: Andrew Haack.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs &amp; Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>_________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Elliot Stone\n\nRecipient Title\n\nPresident\u002FCEO\n\nMedical Products Laboratories, Inc.\n\n9990 Global Road\n\nPhiladelphia, PA 19115\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-61\nApril 9, 2026\nDear Mr. Stone:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Medical Products Laboratories, Inc., FEI 2513595, at 9990 Global Road, Philadelphia, from September 29 to October 16, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nYour firm manufactures and is responsible for introducing or delivering for introduction into interstate commerce in the United States products that are unapproved new drugs in violation of sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. Sections 331(d) and 355(a), including but not limited to: Hydro-Q 4% Gel (hydroquinone 4%); Sodium Sulfacetamide 8% and Sulfur 4% Topical Suspension; Sodium Sulfacetamide 9% and Sulfur 4% Wash; Sodium Sulfacetamide 9.8% Shampoo; Sodium Sulfacetamide 9.8% and Sulfur 4.8% Cleanser; Sodium Sulfacetamide 9.8% and Sulfur 4.8% Lotion; Sodium Sulfacetamide 9.8% and Sulfur 4.8% Cream; Sodium Sulfacetamide 10% and Sulfur 5% Cleanser; Sodium Sulfacetamide 10% Wash; Salicylic Acid 28.5% Solution; Plexion Shampoo (sodium sulfacetamide 9.8%); Plexion Lotion (sodium sulfacetamide 9.8% and sulfur 4.8%), Plexion Cream (sodium sulfacetamide 9.8% and sulfur 4.8%) as prescription drug products. Based on our review, these products are unapproved new drugs under section 505(a) of the FD&C Act, 21 U.S.C. Section 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. Sections 331(d) and 355(a).\nWe reviewed your November 6, 2025 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\nCGMP Violations\n1. Your firm failed to establish and follow appropriate written procedures, designed to prevent objectionable microorganisms in drug products not required to be sterile (21 CFR 211.113(a)).\nMicrobiological Results in Finished Drug Product and (b)(4) Samples\nYour firm manufactures prescription and over-the-counter (OTC) drug products for (b)(4) administration. You failed to adequately establish and follow procedures to prevent contamination with objectionable microorganisms. For example, you used an unvalidated (b)(4) treatment protocol on filled drug product batches in an attempt to reduce microbiological content. Your laboratory reported gross microbiological contamination on plates for both total aerobic microbiological count (TAMC) and total yeast and mold count (TYMC) tests in the following non-sterile finished drug products for (b)(4) administration:\n(b)(4) lot (b)(4) (TAMC: too numerous to count (TNTC) and TYMC: TNTC)\n(b)(4) lot (b)(4) (TAMC: TNTC and TYMC: TNTC)\n(b)(4) lot (b)(4) (TAMC: TNTC and TYMC: (b)(4) colony forming units (CFU) per gram)\nYour investigation of the failing results in (b)(4) lot (b)(4) concluded that contamination was from the (b)(4) component, recovered from a mixture of this component with (b)(4). However, your investigation failed to consider out-of-limit (OOL) microbiological recoveries from your (b)(4) system.\nYou subsequently released drug products based on results from (b)(4) treatment resampling. Your corrective action and preventive action (CAPA) in response to the microbiological contamination included revising the drug product formulation to increase (b)(4) content. (b)(4) are not a substitute for a comprehensive approach to preventing objectionable microorganisms from contaminating your drug products and cannot be relied on to reduce in-process bioburden during manufacturing.\nWe note that on (b)(4), you issued a voluntary recall of (b)(4), lots (b)(4), due to microbiological contamination.\nYour response commits to revising your procedures to no longer allow (b)(4) treatment to rework batches after failing microbiological results and to place a reworked batch on real-time stability. You also include a risk assessment which concludes there is no health risk for two failing lots. Your response is inadequate in that your risk assessment does not extend to all drug products where (b)(4) treatment was attempted, nor does your response provide your plans for addressing product quality and patient safety risks for lots on which you used (b)(4) treatment or product you released after failing microbiological results. Moreover, your response does not address whether additional bacterial species were present, nor did you provide evidence supporting your claims that growth on total yeast and mold plates was solely bacterial.\nThis adverse pattern of microbiological contamination in your drug products demonstrates a significant failure to adhere to CGMP. Unresolved manufacturing and quality problems can pose a significant hazard to patients.\nIn response to this letter, provide:\nA comprehensive, independent assessment of the design and control of your firm’s manufacturing operations, with a detailed and thorough review of all microbiological hazards.\nA detailed risk assessment addressing the hazards posed by distributing drug products with potentially objectionable contamination. Specify actions you will take in response to the risk assessment, such as customer notifications and product recalls.\nComplete investigations into all batches with potential objectionable microbiological contamination or a failing microbiological result (whether or not later invalidated). The investigations should detail your findings regarding the root causes of the contamination.\nAppropriate microbiological batch release specifications (i.e., total counts, identification of bioburden to detect objectionable microbes) for each of your drug products.\nA summary of results from testing retain samples of all drug product batches of which you have received failing, out-of-specification (OOS), OOL or out-of-trend (OOT) microbiological test results. Also provide test results of retains during periods when your (b)(4) system was not operating under a state of control. You should test microbiological quality (total counts and identification of bioburden to detect any objectionable microbes) of each batch. If testing yields any failing, OOS or OOL result, indicate the corrective actions you will take, including notifying customers and initiating recalls.\nA comprehensive remediation plan for the design, control, and maintenance of the (b)(4) system.\no Provide a comprehensive evaluation of vulnerabilities of (b)(4) system design and control, and summarize all deficiencies found in the system. The summary should, at minimum, describe various system characteristics that were assessed for adequacy (system temperature, materials of construction, slope, any identified dead-legs, any stagnant locations, any unsanitary fittings, flow velocity, etc.)\nYour total microbiological count limits to monitor whether this system is producing (b)(4) suitable for the intended uses for each of your products.\nA detailed risk assessment addressing the potential effects of the observed (b)(4) system failures on the quality of all drug product lots currently within expiry. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\n2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\nYou failed to adequately validate your manufacturing processes to demonstrate that your processes are reproducible and controlled to consistently yield drug products of uniform character and quality. For example, you used a process qualification study performed at a different facility to manufacture and release (b)(4). You could not provide evidence your processes (e.g. equipment, components, and manufacturing conditions) were comparable between your facility and the site where initial process validation was performed.\nAdditionally, you failed to adequately validate your process for manufacturing (b)(4). While a process validation study for this product had been initiated, it included insufficient data. At the direction of your customer, you discontinued your efforts to complete process validation for this product, yet you continued manufacturing batches for commercial distribution.\nIn your response, you discuss a retrospective review of (b)(4) batches within expiry. You also indicate that you have paused production of (b)(4) until process validation activities can be completed. You also state that you have updated your process validation procedure and that you have verified that process validation studies have been conducted for drug products you manufacture. Your response is inadequate in that you did not evaluate the implications of changes made to product formulations for drug products that you manufacture.\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\nSuccessful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\nIn response to this letter, provide:\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\nA timeline for performing appropriate PPQ for each of your marketed drug products which lack appropriate studies. Also include an explanation how you will ensure proper satisfactory PPQ studies are performed prior to future distribution of any drug products.\nA risk assessment for the distributed drug products produced without performing any process validation studies or using inadequately validated processes.\nProcess performance protocol(s), and written procedures for qualification of equipment and facilities.\nA detailed program, including your procedure, for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\n3. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\nFinished Drug Product Microbiological Testing\nYour firm failed to adequately investigate failing microbiological results in finished products. For example, your (b)(4) lot (b)(4) obtained a failing result of (b)(4) CFU\u002Fg for TYMC (specification ≤(b)(4) CFU\u002Fg). After your contract testing laboratory failed to identify the fungal species, you concluded, without evidence, that contamination occurred “during handling, transportation and\u002For testing.” You invalidated this failing result based on results of resampling and released the lot.\nMicrobiological contamination may not be uniformly distributed. A product sample may not be representative of the type or level of contamination within the batch. Further, testing the final product for microbiological contamination does not ensure that you have appropriate controls in place to ensure product quality. As a manufacturer, you have a responsibility to fully investigate unexplained discrepancies, deviations, and failures to assess their impact on product quality.\nStability Assay\nYour firm failed to conduct adequate investigations into OOS stability results. For example, in two separate incidents, you invalidated OOS stability results for subpotent assay without adequate scientific justification. You relied on resampling data from (b)(4), lots (b)(4), to invalidate the initial stability OOS result with no identified laboratory error or rationale.\nComplaint Investigations\nYou did not adequately investigate complaints you received. For example, upon receiving complaints of product crystallization in (b)(4), you concluded that this crystallization was due to “transportation and\u002For storage” during winter months. Your investigation failed to consider changes made to the formulation or the status of process validation activities for the formulation.\nIn your response, you commit to reopening complaints of crystallization and discoloration of (b)(4) while pausing manufacturing of this product. You also commit to revising your complaint and investigation procedures, but you did not provide revised procedures. Your response also fails to perform a retrospective review of invalidated OOS results or discuss improperly invalidated results for drug products which remain on the market.\nInadequate investigations can lead to unidentified root causes, ineffective CAPA, and recurring problems that compromise the ability to manufacture safe and effective drug products.\nIn response to this letter, provide:\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\nA retrospective, independent review of all invalidated failing\u002FOOS (including in-process and release\u002Fstability testing) results for U.S. products currently in the U.S. market and within expiry as of the date of this letter and a report summarizing the findings of the analysis, including the following for each OOS:\no Determine whether the scientific justification and evidence relating to the invalidated failing\u002FOOS results conclusively or inconclusively demonstrates causative laboratory error.\no For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\no For all failing\u002FOOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\nA comprehensive review and remediation plan for your failing\u002FOOS result investigation systems. The CAPA should include but not be limited to addressing the following:\no Quality unit oversight of laboratory investigations\no Identification of adverse laboratory control trends\no Resolution of causes of laboratory variation\no Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\no Adequately scoping of each investigation and its CAPA\no Revised failing\u002FOOS investigation procedures with these and other remediations\n4. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\nYour stability program was not adequate to ensure that the drug products you manufacture, maintain their identity, strength, quality, purity, and safety throughout their shelf lives. For example, your stability study for (b)(4) concluded that a (b)(4) expiration is supported at a temperature of (b)(4) to (b)(4) degrees Celsius ((b)(4) to (b)(4) degrees Fahrenheit). However, your firm labeled much wider storage conditions as (b)(4) to (b)(4) degrees Fahrenheit at the instruction of your customer, without adequate data to support the wider labeled storage conditions. We note that you reduced the range of the labeled temperature limits, but they were still outside the range of your stability data.\nIn your response, you committed to revising the stability protocol for this product and placing future lots on stability. You also state that you “can no longer rely on written justifications from product owners to deviate from the general [C]GMP requirements.” Your response is inadequate in that you do not include a comprehensive review of your stability program, nor do you provide your revised stability protocol. Additionally, your response does not describe a retrospective review of batches which lack adequate stability data to support labeled expiration dates and storage conditions.\nWithout the appropriate stability studies, you do not have adequate scientific evidence to support that your drug product retains its quality attributes throughout the labeled (b)(4) expiry period.\nIn response to this letter, provide:\nA comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\no Stability indicating methods\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted\no An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\no A detailed definition of the specific attributes to be tested at each station (timepoint)\no All procedures that describe these and other elements of your remediated stability program.\nUnapproved New Drug Violations\nYour firm’s products are drugs as defined by section 201(g)(1) of the FD&C Act, 21 U.S.C. Section 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For intended to affect the structure or any function of the body.\nExamples from your product labeling that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\nHydro-Q Gel (hydroquinone 4%)\nIndicated for the gradual bleaching of hyperpigmented skin conditions such as chloasma, melasma, freckles, senile lentigines and areas of melanin hyperpigmentation.\nPlexion Shampoo (sodium sulfacetamide 9.8%)\nIntended for topical application in the following scaling dermatoses: seborrheic dermatitis and seborrhea sicca (dandruff).\nPlexion Cream and Plexion Lotion (sodium sulfacetamide 9.8%, sulfur 4.8%)\nIndicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis.\nSodium Sulfacetamide 9.8% Shampoo\nIntended for topical application in the following scaling dermatoses: seborrheic dermatitis and seborrhea sicca (dandruff).\nSodium Sulfacetamide 10% Wash\nIndicated for topical application in the following scaling dermatoses: seborrheic dermatitis and seborrhea sicca (dandruff). It also is indicated for the treatment of secondary bacterial infections of the skin due to organisms susceptible to sulfonamides.\nSodium Sulfacetamide 9.8% and Sulfur 4.8% Cream, Cleanser, and Lotion\nIndicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis.\nSodium Sulfacetamide 8% and Sulfur 4% Topical Suspension\nIndicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis.\nSodium Sulfacetamide 9% and Sulfur 4% Wash\nIndicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis.\nSodium Sulfacetamide 10% and Sulfur 5% Cleanser\nIndicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis.\nSalicylic Acid 28.5% Solution\nIndicated for the topical treatment and removal of common warts and plantar warts.\nYour products are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the above-described conditions prescribed, recommended, or suggested in their labeling.\nWith certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products.\nAccordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nResponsibilities as a Contractor\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\nYou and your customer (b)(4), have a quality agreement regarding the manufacture of (b)(4). You are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\nQuality Systems\nYour firm’s quality systems are inadequate. For guidance on establishing and maintaining CGMP-compliant quality systems, see FDA’s guidances: Q8(R2) Pharmaceutical Development at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71535\u002Fdownload, Q9(R1) Quality Risk Management at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167721\u002Fdownload and Q10 Pharmaceutical Quality System at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71553\u002Fdownload.\nConsultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nFDA requests that you contact CDER's Drug Shortages Staff immediately at drugshortages@fda.hhs.gov so that we can work with you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture, as required under 21 U.S.C.§ 356c(a), and to allow FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who use your products.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days1. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 2513595 and ATTN: Andrew Haack.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n\u002FS\u002F\nTina Smith\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs & Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\n_________________\n1 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","Medical Products Laboratories, Inc.","medical-products-laboratories-inc-721916-04092026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedical-products-laboratories-inc-721916-04092026","2026-10-26T08:09:23.057513+00:00","2026-04-14","721916","Drugs","Mr. Elliot Stone","2026-08-19T04:47:49.417+00:00","VIA UPS","2026-04-09",{"id":54,"raw":55,"subject":12,"body_html":60,"body_text":61,"firm_name":62,"letter_id":63,"created_at":64,"fei_number":19,"letter_url":65,"updated_at":66,"action_type":22,"case_status":67,"posted_date":68,"marcs_cms_no":69,"product_type":26,"closeout_date":70,"issuing_office":11,"recipient_name":71,"body_fetched_at":72,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":73,"medical_device_id":19,"response_letter_date":19},2964,[56,57,58,11,12,13,59,13],"\u003Ctime datetime=\"2021-12-21T14:20:00Z\">12\u002F21\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-11-16T05:00:00Z\">11\u002F16\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fglobal-medical-production-co-ltd-620544-11162021\">Global Medical Production Co Ltd\u003C\u002Fa>","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fglobal-medical-production-co-ltd-620544-05142026\">\u003Ctime datetime=\"2026-05-18T04:00:00Z\">05\u002F18\u002F2026\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jeff Dai General\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Manager &amp; Co-Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Global Medical Production Co Ltd\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>No. 4 Building, No.3288\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>West Zhongshan Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Xiuzhou Qu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Jiaxing Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Zhejiang Sheng\u003C\u002Fspan>, \u003Cspan>314031\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>November 16, 2021\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Dai:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Jiaxing, China on July 15, 2021 through July 30, 2021, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures Sterile and Non-Sterile Electrosurgical Scissors, Sterile Electrosurgical Graspers, and Sterile Veress Pneumoperitoneum Needles. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cstrong>Code of Federal Regulations\u003C\u002Fstrong> (CFR), Part 820. We received two responses from you, dated August 19, 2021 and September 20, 2021, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to establish and maintain adequate procedures to control the design of the device in order to ensure that specified design requirements are met, as required by 21 CFR 820.30(a).\u003C\u002Fp>\n\n\u003Cp>For example, your firm has not established Design Control procedures related to its private label manufactured medical devices intended for the US market to include Class II Sterile and Non-Sterile Electrosurgical Scissors, Class II Sterile Electrosurgical Graspers, and Class II Sterile Veress Pneumoperitoneum Needles. Additionally, your firm was unable to provide documentation and\u002For evidence of conducting Design and Development activities for these medical devices. This is a repeat violation from the previous inspection in April 2015.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Your firm’s response stated that it would conduct training on 21 CFR 820.30 Design Control and Design Control Procedure, and retrospectively establish Design History Files for all products. The response also stated that your firm would provide training records, design history files for all of its products, effectiveness check reports, recommendations for additional actions or closure if applicable, and training records related to these corrective actions. However, the response did not indicate that there would be any assessment to determine the impact of the lack of design control activities for devices that were already distributed. Additionally, your firm has not provided documentation or evidence of implementation of a corrective action plan. The FDA cannot make an assessment with respect to adequacy without such documentation. Please provide evidence of the corrective actions that you outlined in your responses. This information is needed to assess whether these correction actions were completed.\u003C\u002Fp>\n\n\u003Cp>2. Failure to establish and maintain procedures to control product that does not conform to specified requirements as required by 21 CFR 820.90(a).\u003C\u002Fp>\n\n\u003Cp>For example, your firm’s Nonconforming Product Control Procedure, Doc No. 28301, Ver. 2 and dated February 01, 2018; has no requirement for: the evaluation and disposition of nonconforming products, which should include procedures for determination of the need for an investigation and notification of the person or organizations responsible for the nonconformance. Additionally, during the inspection of your firm’s list of 2019-2021 nonconforming products, there was no documentation or evidence that your firm had conducted a determination of the need for an investigation or notification of the persons and organizations responsible for the nonconformance.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Your firm’s response stated that it would revise the Nonconforming Product Procedure Document Number 28301 to add missing information for the evaluation and disposition of nonconforming products, which should include a determination of the need for an investigation and notification of the person or organization responsible for the nonconformance. Your firm also stated that it would retrospectively review the history of Nonconforming product and determine the need for an investigation as well as notification of the persons and organizations responsible for the nonconformance and disposition of the nonconforming product. Additionally, effectiveness checks would be initiated after all corrective and preventive actions were taken.&nbsp; However, the response did not indicate that there would be an assessment to determine if the lack of disposition requirements led to a release of nonconforming product and how that risk will be addressed. Additionally, your firm has not provided documentation or evidence of implementation of the corrective actions as they are still ongoing. The FDA cannot make an assessment with respect to adequacy without such documentation. Please provide evidence of the corrective actions that you outlined in your responses. This information is needed to assess whether these correction actions were completed.\u003C\u002Fp>\n\n\u003Cp>3. Failure to adequately ensure that when the results of a process cannot be fully verified by subsequent inspection and test that the process shall be validated with a high degree of assurance and approved according to established procedure, as required by 21 CFR 820.75(a).\u003C\u002Fp>\n\n\u003Cp>For example, your firm was not able to provide Performance Qualification (PQ) objective data and evidence or results of the PQ activities. Your firm stated that it does not have the results of the PQ conducted for its heat-sealing process validation activities, which is used in manufacturing processes of medical devices exported and intended for the US market. This is a repeat violation from the previous inspection in April 2015.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Your firm’s response stated that it would execute a new Performance Qualification and would also assess all other processes and Performance Qualifications for objective data and results. A new Performance Qualification would be executed where data or results were not found. Your firm stated it would provide the agency with PQ data, its PQ summary Report, effectiveness check reports, recommendations for additional actions or closure if applicable, and training records. However, the response did not indicate that there would be any corrective actions to ensure that the firm maintains such records in the future. Additionally, your firm has not provided documentation or evidence of implementation of the corrective actions as they are still ongoing. The FDA cannot make an assessment with respect to adequacy without such documentation. Please provide evidence of the corrective actions that you outlined in your responses. We request this information to assess whether these correction actions were completed.\u003C\u002Fp>\n\n\u003Cp>4. Failure to conduct periodic inspections in accordance with established procedures to ensure adherence to applicable equipment maintenance schedules, as required by 21 CFR 820.70(g)(1).\u003C\u002Fp>\n\n\u003Cp>For example, your firm has not established a maintenance schedule for your Production Controlled Room Air Handling HEPA Filters and Water Purifier, Equipment No. 08, used in the ultrasonic cleaning of components of your firm’s private label manufactured medical devices intended for the US market, to include Class II Sterile Disposable and Non-Sterile Reusable Electrosurgical Scissors, Class II Sterile Disposable and Non-Sterile Reusable Electrosurgical Graspers, and Class II Sterile Veress Pneumoperitoneum Needles.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Your firm’s response stated that it would establish a maintenance schedule for the Production Controlled Room Air Handling HEPA Filters and Water Purifier Equipment No. 08. Your firm stated that it would provide training for new procedure and provide the agency with records of the retrospective schedule, maintenance schedules, effectiveness check reports and a recommendation for additional actions or closure. However, the response did not indicate that there would be an assessment to determine the impact from the lack of maintenance schedule on previously released product. Additionally, your firm has not provided documentation or evidence of implementation of the corrective actions. The FDA cannot make an assessment with respect to adequacy without such documentation. Please provide evidence of the corrective actions that you outlined in your responses. We request this information to assess whether these correction actions were completed.\u003C\u002Fp>\n\n\u003Cp>5. Failure to identify by suitable means the acceptance status of product, to indicate the conformance or nonconformance of product with acceptance criteria, as required by 21 CFR 820.86.\u003C\u002Fp>\n\n\u003Cp>For example, your firm had product in the warehouse that was labeled as “sterile” and was intended for the U.S. market. However, the product should have been identified as \"Non-Sterile” to indicate its non-processed and non-sterile status to ensure only medical devices that have undergone the sterilization process are accepted and distributed to the US market. Your firm stated that it has no process or requirement to ensure “Non-Sterile” product is conspicuously labeled to indicate its non-processed, non-sterile status from sterile product. Your firm does not follow its Nonconforming Product Control Procedure, Doc No. 28301, Ver. 2 and dated February 01, 2018. Medical device components and finished medical devices were not properly identified to ensure that only product which has passed the required acceptance activities are distributed or used.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Your firm’s response stated that your firm would revise Document 27502, Product Identification and Traceability to add method for identifying the status of product. Your firm also plans to establish a new procedure to address placing the sterile indicator label on the product package to identify product before and after the process of sterilization by December 15, 2021. Your firm will establish a new procedure for physically separating product and identifying each location with product status. Document 28301, section 6.3.2.1 and 6.3.2.2, will be revised to remove sections for green and red labels and replace with a label that has a section to indicate accept or reject status. The Identification Procedure will be revised to include physical storage area status.\u003C\u002Fp>\n\n\u003Cp>A new procedure will be established to identify scrap product with \"not for human use label.\" Your firm will identify storage areas in the facility with proper identification and segregate manufacturing and storage areas to prevent possible mix-ups. Products will be quarantined in the unmarked storage room and assign a Non-Conformance Number to the product, disposition of the product, and identity of the product. Additionally, upon completion of all corrective and preventive actions, your firm will conduct an effectiveness check. Based on results of the effectiveness check, GMP may recommend additional actions or closure of this observation. However, the response did not indicate that there would be an assessment to determine if the lack of adequate identification led to the release of unsterilized product. Additionally, your firm has not provided documentation or evidence of implementation of the corrective actions. The FDA cannot make an assessment with respect to adequacy without such documentation. Please provide evidence of the corrective actions that you outlined in your responses. This information is needed to assess whether these correction actions were completed.\u003C\u002Fp>\n\n\u003Cp>6. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).\u003Cbr>\n\u003Cbr>\nFor example, your firm’s Customer Complaint Control Procedure, Doc No. 28502, Ver. 3, and dated February 01, 2018, has no requirement to ensure your firm is receiving complaints from its sole distributor that is marketing and selling its private label manufactured medical devices in the US market. Additionally, your firm has no documented agreement with its sole US private label distributor requiring them provide your firm with complaints to ensure that it reviews and evaluates all complaints in a uniform and timely manner to determine whether an investigation is necessary and are evaluated to determine whether the complaint represents an event, which is required to be reported to the USFDA under 21 CFR Part 803 - Medical Device Reporting (MDR).\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Your firm stated that it executed a Quality Agreement with its US Distributor that requires the distributor to provide your firm with complaints and provided the agency with a copy of this agreement. Your firm’s response stated that it would revise its Customer Complaint Procedure and retrospectively establish a Customer Complaint Log to record complaint activities. Additionally, the response stated that it would review and evaluate all complaints in a uniform and timely manner to determine whether an investigation is necessary. The response also stated that it would provide the agency with its revised procedure, customer complaint logs, effectiveness check reports, recommendations for additional actions or closure if applicable, and training records related to these corrective actions. However, the response did not indicate that there would be a retrospective assessment to determine if the complaints previously received by the initial importer present quality problems that were previously unknown. Additionally, your firm has not provided documentation or evidence of implementation of the corrective actions. The FDA cannot make an assessment with respect to adequacy without such documentation. Please provide evidence of the corrective actions that you outlined in your responses. This information is needed to assess whether these correction actions were completed.\u003C\u002Fp>\n\n\u003Cp>7. Failure to maintain device master records as required by 820.181.\u003C\u002Fp>\n\n\u003Cp>For example, your firm has not maintained Device Master Records related to your firm's private label manufactured medical devices for the US market to include, Class II Sterile Disposable and Non-Sterile Reusable Electrosurgical Scissors, Class II Sterile Disposable and Non-Sterile Reusable Electrosurgical Graspers and Class II Sterile Veress Pneumoperitoneum Needles.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your firm stated it would conduct training to 21 CFR 820.181 its Quality Manual Procedure Document Number 24101, and retrospectively establish a Device Master Records for all products. The response also stated that it would provide Device Master Records for all products, effectiveness check reports, recommendations for additional actions or closure if applicable, and training records related to these corrective actions. However, your firm has not provided documentation or evidence of implementation of the corrective actions. The FDA cannot make an assessment with respect to adequacy without such documentation. Please provide evidence of the corrective actions that you outlined in your responses. This information is needed to assess whether these correction actions were completed.\u003C\u002Fp>\n\n\u003Cp>8. Failure to maintain device history records as required by 820.184.\u003C\u002Fp>\n\n\u003Cp>For example, your firm was not able to provide device history records for private label manufactured medical devices intended and exported to the US market, to include Class II Sterile Disposable and Non-Sterile Reusable Electrosurgical Scissors, Class II Sterile Disposable and Non-Sterile Reusable Electrosurgical Graspers and Class II Sterile Veress Pneumoperitoneum Needles.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your firm’s response stated that it had a device history record for all of its products but that it had not been translated during the inspection. Your firm stated that it would provide a device history records for each product that it would provide recommendations for additional actions. However, your firm has not provided documentation or evidence of implementation of the corrective actions. The FDA cannot make an assessment with respect to adequacy without such documentation. Please provide evidence of the corrective actions that you outlined in your responses. This information is needed to assess whether these correction actions were completed.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your firm’s devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C.§ 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>Failure to develop, maintain and implement written a Medical Device Reporting (MDR) procedure, as required by 21 CFR 803.17. For example, during the inspection, your firm acknowledged that it does not have an MDR procedure. This is a repeat violation from the previous inspection in April 2015.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. The response noted the following corrective actions: Implement a Medical Device Procedure compliant with 21 CFR 803.17 by September 30, 2021, perform a retrospectively review of all complaints from 2018 to present to evaluate for MDR reportability and submit all the identified MDRs by December 1, 2021 and Perform effectiveness check and report to the FDA within 90 days of completing all corrective and preventative actions. However, your firm has not provided documentation or evidence of implementation of the corrective actions. The FDA cannot make an assessment with respect to adequacy without such documentation. Please provide evidence of the corrective actions that you outlined in your responses. We request this information to assess whether these correction actions were completed.\u003C\u002Fp>\n\n\u003Cp>Given the serious nature of the violations of the Act, Sterile and Non-Sterile Electrosurgical Scissors, Sterile Electrosurgical Graspers, and Sterile Veress Pneumoperitoneum Needles manufactured by your firm are subject to refusal of admission under section 801(a) of the Act, 21 U.S.C. § 381(a), in that they appear to be adulterated. As a result, FDA is taking steps to refuse entry of these devices into the United States, known as “detention without physical examination,” until these violations are addressed. In order to remove the devices from detention, your firm should provide a written response to this Warning Letter as described below and address the violation(s) described in this letter. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent by email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2: Establishment Support, Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case # 620544 when replying. If you have any questions about the contents of this letter, please contact: Long Chen at (301) 796-6389.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Binita S. Ashar, MD, MBA, FACS\u003Cbr>\nDirector\u003Cbr>\nOHT 4: Office of Office of Surgery and\u003Cbr>\nInfection Control Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological\u003Cbr>\nHealth\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nMike Athey\u003Cbr>\n2526 Old Lake Mary Road\u003Cbr>\nSanford, FL 32773\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nJeff Dai General\n\nRecipient Title\n\nManager & Co-Owner\n\nGlobal Medical Production Co Ltd\n\nNo. 4 Building, No.3288\n\nWest Zhongshan Road\n\nXiuzhou Qu\n\nJiaxing Shi\n\nZhejiang Sheng, 314031\n\nChina\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nNovember 16, 2021\n\nDear Mr. Dai:\n\nDuring an inspection of your firm located in Jiaxing, China on July 15, 2021 through July 30, 2021, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures Sterile and Non-Sterile Electrosurgical Scissors, Sterile Electrosurgical Graspers, and Sterile Veress Pneumoperitoneum Needles. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received two responses from you, dated August 19, 2021 and September 20, 2021, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to establish and maintain adequate procedures to control the design of the device in order to ensure that specified design requirements are met, as required by 21 CFR 820.30(a).\n\nFor example, your firm has not established Design Control procedures related to its private label manufactured medical devices intended for the US market to include Class II Sterile and Non-Sterile Electrosurgical Scissors, Class II Sterile Electrosurgical Graspers, and Class II Sterile Veress Pneumoperitoneum Needles. Additionally, your firm was unable to provide documentation and\u002For evidence of conducting Design and Development activities for these medical devices. This is a repeat violation from the previous inspection in April 2015.\n\nWe reviewed your firm’s response and conclude that it is not adequate. Your firm’s response stated that it would conduct training on 21 CFR 820.30 Design Control and Design Control Procedure, and retrospectively establish Design History Files for all products. The response also stated that your firm would provide training records, design history files for all of its products, effectiveness check reports, recommendations for additional actions or closure if applicable, and training records related to these corrective actions. However, the response did not indicate that there would be any assessment to determine the impact of the lack of design control activities for devices that were already distributed. Additionally, your firm has not provided documentation or evidence of implementation of a corrective action plan. The FDA cannot make an assessment with respect to adequacy without such documentation. Please provide evidence of the corrective actions that you outlined in your responses. This information is needed to assess whether these correction actions were completed.\n\n2. Failure to establish and maintain procedures to control product that does not conform to specified requirements as required by 21 CFR 820.90(a).\n\nFor example, your firm’s Nonconforming Product Control Procedure, Doc No. 28301, Ver. 2 and dated February 01, 2018; has no requirement for: the evaluation and disposition of nonconforming products, which should include procedures for determination of the need for an investigation and notification of the person or organizations responsible for the nonconformance. Additionally, during the inspection of your firm’s list of 2019-2021 nonconforming products, there was no documentation or evidence that your firm had conducted a determination of the need for an investigation or notification of the persons and organizations responsible for the nonconformance.\n\nWe reviewed your firm’s response and conclude that it is not adequate. Your firm’s response stated that it would revise the Nonconforming Product Procedure Document Number 28301 to add missing information for the evaluation and disposition of nonconforming products, which should include a determination of the need for an investigation and notification of the person or organization responsible for the nonconformance. Your firm also stated that it would retrospectively review the history of Nonconforming product and determine the need for an investigation as well as notification of the persons and organizations responsible for the nonconformance and disposition of the nonconforming product. Additionally, effectiveness checks would be initiated after all corrective and preventive actions were taken. However, the response did not indicate that there would be an assessment to determine if the lack of disposition requirements led to a release of nonconforming product and how that risk will be addressed. Additionally, your firm has not provided documentation or evidence of implementation of the corrective actions as they are still ongoing. The FDA cannot make an assessment with respect to adequacy without such documentation. Please provide evidence of the corrective actions that you outlined in your responses. This information is needed to assess whether these correction actions were completed.\n\n3. Failure to adequately ensure that when the results of a process cannot be fully verified by subsequent inspection and test that the process shall be validated with a high degree of assurance and approved according to established procedure, as required by 21 CFR 820.75(a).\n\nFor example, your firm was not able to provide Performance Qualification (PQ) objective data and evidence or results of the PQ activities. Your firm stated that it does not have the results of the PQ conducted for its heat-sealing process validation activities, which is used in manufacturing processes of medical devices exported and intended for the US market. This is a repeat violation from the previous inspection in April 2015.\n\nWe reviewed your firm’s response and conclude that it is not adequate. Your firm’s response stated that it would execute a new Performance Qualification and would also assess all other processes and Performance Qualifications for objective data and results. A new Performance Qualification would be executed where data or results were not found. Your firm stated it would provide the agency with PQ data, its PQ summary Report, effectiveness check reports, recommendations for additional actions or closure if applicable, and training records. However, the response did not indicate that there would be any corrective actions to ensure that the firm maintains such records in the future. Additionally, your firm has not provided documentation or evidence of implementation of the corrective actions as they are still ongoing. The FDA cannot make an assessment with respect to adequacy without such documentation. Please provide evidence of the corrective actions that you outlined in your responses. We request this information to assess whether these correction actions were completed.\n\n4. Failure to conduct periodic inspections in accordance with established procedures to ensure adherence to applicable equipment maintenance schedules, as required by 21 CFR 820.70(g)(1).\n\nFor example, your firm has not established a maintenance schedule for your Production Controlled Room Air Handling HEPA Filters and Water Purifier, Equipment No. 08, used in the ultrasonic cleaning of components of your firm’s private label manufactured medical devices intended for the US market, to include Class II Sterile Disposable and Non-Sterile Reusable Electrosurgical Scissors, Class II Sterile Disposable and Non-Sterile Reusable Electrosurgical Graspers, and Class II Sterile Veress Pneumoperitoneum Needles.\n\nWe reviewed your firm’s response and conclude that it is not adequate. Your firm’s response stated that it would establish a maintenance schedule for the Production Controlled Room Air Handling HEPA Filters and Water Purifier Equipment No. 08. Your firm stated that it would provide training for new procedure and provide the agency with records of the retrospective schedule, maintenance schedules, effectiveness check reports and a recommendation for additional actions or closure. However, the response did not indicate that there would be an assessment to determine the impact from the lack of maintenance schedule on previously released product. Additionally, your firm has not provided documentation or evidence of implementation of the corrective actions. The FDA cannot make an assessment with respect to adequacy without such documentation. Please provide evidence of the corrective actions that you outlined in your responses. We request this information to assess whether these correction actions were completed.\n\n5. Failure to identify by suitable means the acceptance status of product, to indicate the conformance or nonconformance of product with acceptance criteria, as required by 21 CFR 820.86.\n\nFor example, your firm had product in the warehouse that was labeled as “sterile” and was intended for the U.S. market. However, the product should have been identified as \"Non-Sterile” to indicate its non-processed and non-sterile status to ensure only medical devices that have undergone the sterilization process are accepted and distributed to the US market. Your firm stated that it has no process or requirement to ensure “Non-Sterile” product is conspicuously labeled to indicate its non-processed, non-sterile status from sterile product. Your firm does not follow its Nonconforming Product Control Procedure, Doc No. 28301, Ver. 2 and dated February 01, 2018. Medical device components and finished medical devices were not properly identified to ensure that only product which has passed the required acceptance activities are distributed or used.\n\nWe reviewed your firm’s response and conclude that it is not adequate. Your firm’s response stated that your firm would revise Document 27502, Product Identification and Traceability to add method for identifying the status of product. Your firm also plans to establish a new procedure to address placing the sterile indicator label on the product package to identify product before and after the process of sterilization by December 15, 2021. Your firm will establish a new procedure for physically separating product and identifying each location with product status. Document 28301, section 6.3.2.1 and 6.3.2.2, will be revised to remove sections for green and red labels and replace with a label that has a section to indicate accept or reject status. The Identification Procedure will be revised to include physical storage area status.\n\nA new procedure will be established to identify scrap product with \"not for human use label.\" Your firm will identify storage areas in the facility with proper identification and segregate manufacturing and storage areas to prevent possible mix-ups. Products will be quarantined in the unmarked storage room and assign a Non-Conformance Number to the product, disposition of the product, and identity of the product. Additionally, upon completion of all corrective and preventive actions, your firm will conduct an effectiveness check. Based on results of the effectiveness check, GMP may recommend additional actions or closure of this observation. However, the response did not indicate that there would be an assessment to determine if the lack of adequate identification led to the release of unsterilized product. Additionally, your firm has not provided documentation or evidence of implementation of the corrective actions. The FDA cannot make an assessment with respect to adequacy without such documentation. Please provide evidence of the corrective actions that you outlined in your responses. This information is needed to assess whether these correction actions were completed.\n\n6. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).\n\nFor example, your firm’s Customer Complaint Control Procedure, Doc No. 28502, Ver. 3, and dated February 01, 2018, has no requirement to ensure your firm is receiving complaints from its sole distributor that is marketing and selling its private label manufactured medical devices in the US market. Additionally, your firm has no documented agreement with its sole US private label distributor requiring them provide your firm with complaints to ensure that it reviews and evaluates all complaints in a uniform and timely manner to determine whether an investigation is necessary and are evaluated to determine whether the complaint represents an event, which is required to be reported to the USFDA under 21 CFR Part 803 - Medical Device Reporting (MDR).\n\nWe reviewed your firm’s response and conclude that it is not adequate. Your firm stated that it executed a Quality Agreement with its US Distributor that requires the distributor to provide your firm with complaints and provided the agency with a copy of this agreement. Your firm’s response stated that it would revise its Customer Complaint Procedure and retrospectively establish a Customer Complaint Log to record complaint activities. Additionally, the response stated that it would review and evaluate all complaints in a uniform and timely manner to determine whether an investigation is necessary. The response also stated that it would provide the agency with its revised procedure, customer complaint logs, effectiveness check reports, recommendations for additional actions or closure if applicable, and training records related to these corrective actions. However, the response did not indicate that there would be a retrospective assessment to determine if the complaints previously received by the initial importer present quality problems that were previously unknown. Additionally, your firm has not provided documentation or evidence of implementation of the corrective actions. The FDA cannot make an assessment with respect to adequacy without such documentation. Please provide evidence of the corrective actions that you outlined in your responses. This information is needed to assess whether these correction actions were completed.\n\n7. Failure to maintain device master records as required by 820.181.\n\nFor example, your firm has not maintained Device Master Records related to your firm's private label manufactured medical devices for the US market to include, Class II Sterile Disposable and Non-Sterile Reusable Electrosurgical Scissors, Class II Sterile Disposable and Non-Sterile Reusable Electrosurgical Graspers and Class II Sterile Veress Pneumoperitoneum Needles.\n\nThe adequacy of your firm’s response cannot be determined at this time. Your firm stated it would conduct training to 21 CFR 820.181 its Quality Manual Procedure Document Number 24101, and retrospectively establish a Device Master Records for all products. The response also stated that it would provide Device Master Records for all products, effectiveness check reports, recommendations for additional actions or closure if applicable, and training records related to these corrective actions. However, your firm has not provided documentation or evidence of implementation of the corrective actions. The FDA cannot make an assessment with respect to adequacy without such documentation. Please provide evidence of the corrective actions that you outlined in your responses. This information is needed to assess whether these correction actions were completed.\n\n8. Failure to maintain device history records as required by 820.184.\n\nFor example, your firm was not able to provide device history records for private label manufactured medical devices intended and exported to the US market, to include Class II Sterile Disposable and Non-Sterile Reusable Electrosurgical Scissors, Class II Sterile Disposable and Non-Sterile Reusable Electrosurgical Graspers and Class II Sterile Veress Pneumoperitoneum Needles.\n\nThe adequacy of your firm’s response cannot be determined at this time. Your firm’s response stated that it had a device history record for all of its products but that it had not been translated during the inspection. Your firm stated that it would provide a device history records for each product that it would provide recommendations for additional actions. However, your firm has not provided documentation or evidence of implementation of the corrective actions. The FDA cannot make an assessment with respect to adequacy without such documentation. Please provide evidence of the corrective actions that you outlined in your responses. This information is needed to assess whether these correction actions were completed.\n\nOur inspection also revealed that your firm’s devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C.§ 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\n\nFailure to develop, maintain and implement written a Medical Device Reporting (MDR) procedure, as required by 21 CFR 803.17. For example, during the inspection, your firm acknowledged that it does not have an MDR procedure. This is a repeat violation from the previous inspection in April 2015.\n\nThe adequacy of your firm’s response cannot be determined at this time. The response noted the following corrective actions: Implement a Medical Device Procedure compliant with 21 CFR 803.17 by September 30, 2021, perform a retrospectively review of all complaints from 2018 to present to evaluate for MDR reportability and submit all the identified MDRs by December 1, 2021 and Perform effectiveness check and report to the FDA within 90 days of completing all corrective and preventative actions. However, your firm has not provided documentation or evidence of implementation of the corrective actions. The FDA cannot make an assessment with respect to adequacy without such documentation. Please provide evidence of the corrective actions that you outlined in your responses. We request this information to assess whether these correction actions were completed.\n\nGiven the serious nature of the violations of the Act, Sterile and Non-Sterile Electrosurgical Scissors, Sterile Electrosurgical Graspers, and Sterile Veress Pneumoperitoneum Needles manufactured by your firm are subject to refusal of admission under section 801(a) of the Act, 21 U.S.C. § 381(a), in that they appear to be adulterated. As a result, FDA is taking steps to refuse entry of these devices into the United States, known as “detention without physical examination,” until these violations are addressed. In order to remove the devices from detention, your firm should provide a written response to this Warning Letter as described below and address the violation(s) described in this letter. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent by email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2: Establishment Support, Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case # 620544 when replying. If you have any questions about the contents of this letter, please contact: Long Chen at (301) 796-6389.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nBinita S. Ashar, MD, MBA, FACS\n\nDirector\n\nOHT 4: Office of Office of Surgery and\n\nInfection Control Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological\n\nHealth\n\nCC:\n\nMike Athey\n\n2526 Old Lake Mary Road\n\nSanford, FL 32773","Global Medical Production Co Ltd","global-medical-production-co-ltd-620544-11162021","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fglobal-medical-production-co-ltd-620544-11162021","2026-10-26T08:08:46.668846+00:00","Closed Out","2021-12-21","620544","2026-05-18","Jeff Dai General","2026-08-20T02:18:38.641+00:00","2021-11-16",{"id":75,"raw":76,"subject":12,"body_html":80,"body_text":81,"firm_name":82,"letter_id":83,"created_at":84,"fei_number":19,"letter_url":85,"updated_at":86,"action_type":22,"case_status":23,"posted_date":87,"marcs_cms_no":88,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":89,"body_fetched_at":90,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":87,"medical_device_id":19,"response_letter_date":19},1362,[77,78,79,11,12,13,13,13],"\u003Ctime datetime=\"2024-07-18T18:00:00Z\">07\u002F18\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-07-18T04:00:00Z\">07\u002F18\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fjiangsu-shenli-medical-production-co-ltd-687035-07182024\">Jiangsu Shenli Medical Production Co., Ltd.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Liqun Yang\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Jiangsu Shenli Medical Production Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>No. 20 Changzheng Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Zhengluzhen\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Wujin Qu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Changzhou Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Jiangsu Sheng\u003C\u002Fspan>,\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\n&nbsp;\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Liqun Yang,\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm Jiangsu Shenli Medical Production Co., Ltd., located at No. 20 Changzheng Road, Zhengluzhen, Wujin, Changzhou, Jiangsu, China on March 25 through March 29, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a contract and private label manufacturer of sterile and non-sterile syringes, intended to inject fluids into or withdraw fluids from the body. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\u003C\u002Fp>\n\n\u003Cp>We received responses from Liqun Yang dated April 17, 2024, April 30, 2024, and May 30, 2024, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Quality System Regulation Violations\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>1. Failure to establish and maintain procedures to control the design of the device in order to ensure that specified design requirements are met, as required by 21 CFR 820.30(a)(1).\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has no documentation related to design and development activities for your bulk Non-Sterile Luer Lock syringe sizes 3 mL, 5 mL, 10 mL, 20 mL, 30 mL, and 60 mL; Sterile Luer Lock syringe sizes 3 mL, 6 mL, 12 mL, 20 mL, 35 mL, 60 mL, 100 mL; and bulk Non-Sterile Luer Slip syringe sizes 1 mL, 3 mL, 5 mL, 10 mL, 20 mL, 30 mL, and 60 mL, exported and intended for the US market that includes:\u003Cbr>\n&nbsp; a. Design Input\u003Cbr>\n&nbsp; b. Design Output\u003Cbr>\n&nbsp; c. Design Review\u003Cbr>\n&nbsp; d. Design Verification\u003Cbr>\n&nbsp; e. Design Validation to include Risk Analysis\u003Cbr>\n&nbsp; f. Design Transfer\u003Cbr>\n&nbsp; g. Design Changes\u003Cbr>\n&nbsp; h. Design History File\u003C\u002Fp>\n\n\u003Cp>Additionally, your firm has no design and development documentation for your Enteral Feeding Syringes with ENfit connector Model: 10 ml and 60 ml control ring.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s responses cannot be determined at this time. Your responses indicate that you have opened CAPA 2024-0407 to address this citation and that the design and development procedure will be revised to ensure alignment with the necessary requirements related to design planning, input, output, review, verification, validation, transfer, and changes, and that you will verify that other products being exported to the United States contain a DHF. However, documentation or evidence of completed corrective actions was not provided, including the results of your retrospective analysis of other products as well as corrective actions conducted as a result of your investigation into the root-cause(s) associated with the failure to implement your design control procedures, and verification and\u002For validation that the corrective actions (including implementation of design controls for all products that currently lack them) were effective, prior to their implementation, to prevent recurrence of these violations.\u003C\u002Fp>\n\n\u003Cp>2. Failure to establish and maintain device master records, as required by 21 CFR 820.181.\u003C\u002Fp>\n\n\u003Cp>Specifically, you have not established a Device Master Record (DMR) for your line of private label manufactured syringes under K103830 and syringes with various colors, sizes and connection types without market clearance or approval exported and intended for the US market. Your firm has no documentation to include:\u003C\u002Fp>\n\n\u003Cp>&nbsp; a. Device specifications including appropriate drawings, composition, formulation, and component specifications;\u003Cbr>\n&nbsp; b. Production process specifications including the appropriate equipment specifications, production methods, production procedures, and production environment specifications;\u003Cbr>\n&nbsp; c. Quality assurance procedures and specifications including acceptance criteria and the quality assurance equipment to be used;\u003Cbr>\n&nbsp; d. Packaging and labeling specifications, including methods and processes used; and\u003Cbr>\n&nbsp; e. Installation, maintenance, and servicing procedures and methods.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s responses cannot be determined at this time. Your responses indicate that you have opened CAPA 2024-0406 to address this observation, and mentioned that you will establish a DMR procedure, train relevant personnel, submit a new 510k submission for syringes outside the scope of K103830 cleared products, and organize DMRs for other 510ks not related to K103830. However, documentation or evidence of completed corrective actions was not provided, including but not limited to, evidence of completion of the activities proposed in your remediation plan and documentation demonstrating that your corrective actions have been evaluated for effectiveness.\u003C\u002Fp>\n\n\u003Cp>Given the serious nature of the violations of the Act, sterile and non-sterile syringes manufactured by your firm are subject to refusal of admission under section 801(a) of the Act, 21 U.S.C. § 381(a), in that they appear to be adulterated. As a result, FDA has taken steps to refuse entry of devices under product code FMF into the United States, known as “detention without physical examination.” FDA will take steps to refuse entry of additional devices under product code PNR into the United States, known as “detention without physical examination,” until these violations are addressed. In order to remove the devices from detention, your firm should provide a written response to this Warning Letter as described below and address the violation(s) described in this letter. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent by email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2: Establishment Support, Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. \u003Cstrong>Refer to CMS case # 687035 when replying\u003C\u002Fstrong>. If you have any questions about the contents of this letter, please contact: \u003Cstrong>Shruti Mistry\u003C\u002Fstrong> at shruti.mistry@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Kellie B. Kelm, Ph.D.\u003Cbr>\nActing Director\u003Cbr>\nOHT3: Office of GastroRenal, ObGyn,\u003Cbr>\nGeneral Hospital and Urology Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>Cc:\u003Cbr>\n\u003Cstrong>Official correspondent:\u003C\u002Fstrong>\u003Cbr>\nJill Sun at jill.sun@syringechina.com\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>US Agent:\u003C\u002Fstrong>\u003Cbr>\nCharles Mack\u003Cbr>\nIRC USA\u003Cbr>\n2950 E Lindrick Dr\u003Cbr>\nChandler, AZ, US 85249\u003Cbr>\nEmail: Ircfda@Gmail.Com or findingchina@gmail.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nLiqun Yang\n\nRecipient Title\n\nGeneral Manager\n\nJiangsu Shenli Medical Production Co., Ltd.\n\nNo. 20 Changzheng Road\n\nZhengluzhen\n\nWujin Qu\n\nChangzhou Shi\n\nJiangsu Sheng,\n\nChina\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nDear Mr. Liqun Yang,\n\nDuring an inspection of your firm Jiangsu Shenli Medical Production Co., Ltd., located at No. 20 Changzheng Road, Zhengluzhen, Wujin, Changzhou, Jiangsu, China on March 25 through March 29, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a contract and private label manufacturer of sterile and non-sterile syringes, intended to inject fluids into or withdraw fluids from the body. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\n\nWe received responses from Liqun Yang dated April 17, 2024, April 30, 2024, and May 30, 2024, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\nQuality System Regulation Violations\n\n1. Failure to establish and maintain procedures to control the design of the device in order to ensure that specified design requirements are met, as required by 21 CFR 820.30(a)(1).\n\nSpecifically, your firm has no documentation related to design and development activities for your bulk Non-Sterile Luer Lock syringe sizes 3 mL, 5 mL, 10 mL, 20 mL, 30 mL, and 60 mL; Sterile Luer Lock syringe sizes 3 mL, 6 mL, 12 mL, 20 mL, 35 mL, 60 mL, 100 mL; and bulk Non-Sterile Luer Slip syringe sizes 1 mL, 3 mL, 5 mL, 10 mL, 20 mL, 30 mL, and 60 mL, exported and intended for the US market that includes:\n\na. Design Input\n\nb. Design Output\n\nc. Design Review\n\nd. Design Verification\n\ne. Design Validation to include Risk Analysis\n\nf. Design Transfer\n\ng. Design Changes\n\nh. Design History File\n\nAdditionally, your firm has no design and development documentation for your Enteral Feeding Syringes with ENfit connector Model: 10 ml and 60 ml control ring.\n\nThe adequacy of your firm’s responses cannot be determined at this time. Your responses indicate that you have opened CAPA 2024-0407 to address this citation and that the design and development procedure will be revised to ensure alignment with the necessary requirements related to design planning, input, output, review, verification, validation, transfer, and changes, and that you will verify that other products being exported to the United States contain a DHF. However, documentation or evidence of completed corrective actions was not provided, including the results of your retrospective analysis of other products as well as corrective actions conducted as a result of your investigation into the root-cause(s) associated with the failure to implement your design control procedures, and verification and\u002For validation that the corrective actions (including implementation of design controls for all products that currently lack them) were effective, prior to their implementation, to prevent recurrence of these violations.\n\n2. Failure to establish and maintain device master records, as required by 21 CFR 820.181.\n\nSpecifically, you have not established a Device Master Record (DMR) for your line of private label manufactured syringes under K103830 and syringes with various colors, sizes and connection types without market clearance or approval exported and intended for the US market. Your firm has no documentation to include:\n\na. Device specifications including appropriate drawings, composition, formulation, and component specifications;\n\nb. Production process specifications including the appropriate equipment specifications, production methods, production procedures, and production environment specifications;\n\nc. Quality assurance procedures and specifications including acceptance criteria and the quality assurance equipment to be used;\n\nd. Packaging and labeling specifications, including methods and processes used; and\n\ne. Installation, maintenance, and servicing procedures and methods.\n\nThe adequacy of your firm’s responses cannot be determined at this time. Your responses indicate that you have opened CAPA 2024-0406 to address this observation, and mentioned that you will establish a DMR procedure, train relevant personnel, submit a new 510k submission for syringes outside the scope of K103830 cleared products, and organize DMRs for other 510ks not related to K103830. However, documentation or evidence of completed corrective actions was not provided, including but not limited to, evidence of completion of the activities proposed in your remediation plan and documentation demonstrating that your corrective actions have been evaluated for effectiveness.\n\nGiven the serious nature of the violations of the Act, sterile and non-sterile syringes manufactured by your firm are subject to refusal of admission under section 801(a) of the Act, 21 U.S.C. § 381(a), in that they appear to be adulterated. As a result, FDA has taken steps to refuse entry of devices under product code FMF into the United States, known as “detention without physical examination.” FDA will take steps to refuse entry of additional devices under product code PNR into the United States, known as “detention without physical examination,” until these violations are addressed. In order to remove the devices from detention, your firm should provide a written response to this Warning Letter as described below and address the violation(s) described in this letter. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent by email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2: Establishment Support, Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case # 687035 when replying. If you have any questions about the contents of this letter, please contact: Shruti Mistry at shruti.mistry@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nKellie B. Kelm, Ph.D.\n\nActing Director\n\nOHT3: Office of GastroRenal, ObGyn,\n\nGeneral Hospital and Urology Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCc:\n\nOfficial correspondent:\n\nJill Sun at jill.sun@syringechina.com\n\nUS Agent:\n\nCharles Mack\n\nIRC USA\n\n2950 E Lindrick Dr\n\nChandler, AZ, US 85249\n\nEmail: Ircfda@Gmail.Com or findingchina@gmail.com","Jiangsu Shenli Medical Production Co., Ltd.","jiangsu-shenli-medical-production-co-ltd-687035-07182024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fjiangsu-shenli-medical-production-co-ltd-687035-07182024","2026-10-26T08:09:04.177357+00:00","2024-07-18","687035","Liqun Yang","2026-08-19T23:57:23.806+00:00",{"id":92,"raw":93,"subject":97,"body_html":98,"body_text":99,"firm_name":82,"letter_id":100,"created_at":101,"fei_number":19,"letter_url":102,"updated_at":103,"action_type":22,"case_status":23,"posted_date":104,"marcs_cms_no":105,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":89,"body_fetched_at":106,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":107,"medical_device_id":19,"response_letter_date":19},1557,[94,95,96,11,97,13,13,13],"\u003Ctime datetime=\"2024-03-19T18:00:00Z\">03\u002F19\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-03-18T04:00:00Z\">03\u002F18\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fjiangsu-shenli-medical-production-co-ltd-677753-03182024\">Jiangsu Shenli Medical Production Co., Ltd.\u003C\u002Fa>","CGMP\u002FQSR\u002FMedical Devices\u002FPMA\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Liqun Yang\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Jiangsu Shenli Medical Production Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>No. 20 Changzheng Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Zhengluzhen\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Wujin Qu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Changzhou Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Jiangsu Sheng\u003C\u002Fspan>,\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(4)\"> (b)(4)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER \u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CMS # 677753\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>March 11, 2024\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Yang,\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) has learned that your firm is marketing Jiangsu Shenli Medical Production Co. Ltd. piston syringes of the sizes and configurations listed in Table 1 below in the United States without marketing clearance or approval, in violation of the Federal Food, Drug, and Cosmetic Act (the Act).\u003C\u002Fp>\n\n\u003Ctable>\n\t\u003Ctbody>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cstrong>Model #\u003C\u002Fstrong>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cstrong>Item Description\u003C\u002Fstrong>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cstrong>Model #\u003C\u002Fstrong>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cstrong>Item Description\u003C\u002Fstrong>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>83077\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 30ML L\u002FS\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91839\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 20ML L\u002FL YELLOW\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>83078\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 30ML L\u002FL\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91840\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 3ML L\u002FL PURPLE\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>83079\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 60ML L\u002FS\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91841\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 5ML L\u002FL PURPLE\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>83080\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 60ML L\u002FL\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91842\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL PURPLE\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>83081\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FS\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91845\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 20ML L\u002FL BLUE SALINE\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>83082\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91846\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL YELLOW CONT\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>83083\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 3ML L\u002FS\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91847\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL BLUE LIDO\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>83084\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 3ML L\u002FL\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91849\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL BLUE SALINE\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>83085\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 5ML L\u002FS\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91850\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL RED LIDO\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>83087\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 20ML L\u002FS\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91851\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL RED HEPARIN\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>83088\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 20ML L\u002FL\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91852\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 5ML L\u002FL YELLOW NITRO\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>83089\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 1ML TB\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91854\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL YELLOW LIDO\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91820\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 3ML L\u002FL RED\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91855\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL YELLOW HEP\u002FSALINE\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91821\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 3ML L\u002FL GREEN\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91856\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL RED CONT\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91822\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 3ML L\u002FL BLUE\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91857\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL GREEN CONT\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91825\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 5ML L\u002FL RED\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91858\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 20ML L\u002FL WHITE SALINE\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91826\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 5ML L\u002FL GREEN\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91859\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 5ML L\u002FL PURPLE NITRO\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91827\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 5ML L\u002FL BLUE\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91863\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 20ML L\u002FL YELLOW LIDO\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91828\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 5ML L\u002FL WHITE\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91866\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 5ML L\u002FL RED NITRO\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91829\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 5ML L\u002FL YELLOW\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91867\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 5ML L\u002FL BLUE HEPARIN\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91830\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL RED\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91872\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FS BLUE\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91831\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL GREEN\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91873\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL WHITE LIDO\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91832\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL BLUE\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91874\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FS RED\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91833\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL WHITE\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91876\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR CNTRL 10ML L\u002FL YEL 1\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91834\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL YELLOW\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91877\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR CNTRL 10ML L\u002FIL YELLOW LIDO\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91835\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 20ML L\u002FL RED\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91878\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR CNTRL 10 ML L\u002FL RED\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91836\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 20ML L\u002FL GREEN\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91879\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR CNTRL 10ML L\u002FL GRN\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91837\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 20ML L\u002FL BLUE\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91880\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR CNTRL 10ML L\u002FL BLUE\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91838\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 20ML L\u002FL WHITE\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91881\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL CONTROL\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\u003C\u002Ftbody>\n\u003C\u002Ftable>\n\n\u003Cp>\u003Cstrong>Table 1.\u003C\u002Fstrong> List of Jiangsu Shenli Medical Production Co. Ltd. piston syringe configurations implicated in this Warning Letter.\u003C\u002Fp>\n\n\u003Cp>Under section 201(h) of the Act, 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>FDA has determined, based on information provided by your firm and information available on the Agency's public databases, that the Jiangsu Shenli Medical Production Co. Ltd. piston syringes configurations listed in \u003Cstrong>Table 1\u003C\u002Fstrong> are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(0(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). The devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution these devices with (1) major changes or modifications to the intended use, and\u002For (2) a change or modification in the device that could significantly affect the safety or effectiveness of the device without submitting a premarket notification to FDA as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3)(i)-(ii).\u003C\u002Fp>\n\n\u003Cp>Specifically, the Jiangsu Shenli Medical Production Co. Ltd. Piston Syringe (5cc Luer Lock) was cleared under K103830 with the following indications for use: The intended use of the Jiangsu Shenli Medical Production Co., Ltd. 5cc luer lock piston syringe is to inject fluids into or withdraw fluids from the body. Based on FDA's evaluation of your firm's activities, there is evidence that your firm is engaged in the distribution of syringes for use within the United States with substantially different technological characteristics, namely sizes other than 5 mL, luer slip instead of luer lock tips, syringes intended for specific drugs, different colors (i.e., colorants), and control syringes, each of which constitute a significant change or modification in design that could significantly alter the safety or effectiveness of the device. For further explanation on the need for a new premarket notification, or \"510(k),\" for changes to the intended use or design affecting safety and effectiveness, it is recommended you consult the guidance document \"Deciding When to Submit a 510(k) for a Change to an Existing Device — Guidance for Industry and Food and Drug Administration Staff (fda.gov).\" In the guidance at Figure 3 — Flowchart B: Technology, Engineering, and Performance Changes, FDA explains why changes in size, color, specific drug indications and connector type all constitute a major change or modification to the device's intended use, for which your firm lacks clearance or approval.\u003C\u002Fp>\n\n\u003Cp>As discussed above the products listed in \u003Cstrong>Table 1\u003C\u002Fstrong> are misbranded because you made one or more change(s) or modification(s) to each device that could significantly affect the safety or effectiveness of the device without submitting a 510(k) to FDA. Specifically, changing the volume of the syringe, switching from a luer lock to a luer slip syringe tip, and changing from a traditional syringe to a control syringe could result in the risk of patient harm such as inaccurate dosing, a leaking device, a higher risk of inappropriate needle detachment, and incorrect device handling. Furthermore, the addition of color additives to your syringe could result in adverse health effects such as allergic reactions, skin irritation or inflammation, pain, fever, red blood cell damage that induces organ stress, and toxicity that leads to loss of organ function or failure. Labeling the syringe for a specific drug can also cause harm because differences in drug viscosities impact the function of the syringe and can result in patient harm such as inaccurate dosing or incorrect drug usage.\u003C\u002Fp>\n\n\u003Cp>Your firm's failure to submit 510(k)s for these devices has prevented FDA from evaluating the risks posed by these substantially different technological characteristics or from determining that there is reasonable assurance of the safety and effectiveness of these modified devices such that they may be legally marketed syringes. Further, FDA has observed evidence of postmarket safety signals indicating product quality issues that have the potential to cause serious patient harm. Specifically, FDA is aware of multiple customer complaints regarding quality issues (e.g. cracks, breakage during use) for syringes in surgical kits supplied by Jiangsu Shenli Medical Production Co. Ltd.\u003C\u002Fp>\n\n\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>FDA requests that Jiangsu Shenli Medical Production Factory cease any activities that result in the misbranding or adulteration of all the Jiangsu Shenli Medical Production Co. Ltd. piston syringe configurations listed in \u003Cstrong>Table 1\u003C\u002Fstrong>, such as the commercial distribution of the device sizes, configurations, and uses discussed above, including selling to initial importers, distributors, or other third parties for distribution and use within the United States or otherwise representing these devices to have the requisite clearance or authorization for marketing in the United States.\u003C\u002Fp>\n\n\u003Cp>Given the serious nature of the violations of the Act and growing evidence of potential harm, all the Jiangsu Shenli Medical Production Co. Ltd. piston syringes configurations listed in \u003Cstrong>Table 1\u003C\u002Fstrong> are subject to refusal of admission under section 801(a) of the Act, 21 U.S.C. § 381(a), in that they appear to be adulterated. As a result, FDA is taking steps to refuse entry of these devices into the United States, until these violations are addressed.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) your firm has taken. If your firm's planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm's response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm's response should be sent by email to CDRHWamingLetterResponses@fda.hhs.gov or by mail to:\u003C\u002Fp>\n\n\u003Cp>Food and Drug Administration\u003Cbr>\nCenter for Devices and Radiological Health\u003Cbr>\nOffice of Regulatory Programs\u003Cbr>\nDivision of Regulatory Programs 2: Establishment Support\u003Cbr>\nRegulatory Inspections and Audits Team\u003Cbr>\nWhite Oak Building 66\u003Cbr>\n10903 New Hampshire Ave.\u003Cbr>\nSilver Spring, MD 20993\u003C\u002Fp>\n\n\u003Cp>Refer to the identification number \u003Cstrong>CMS # 677753\u003C\u002Fstrong> when replying. We remind you that only written communication is considered as official. If you have any questions about the contents of this letter, please contact: Shruti Misty at Shruti.Mistry@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm. It is your firm's responsibility to ensure compliance with the applicable laws and regulations administered by FDA.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Kellie B. Kelm, Ph.D.\u003Cbr>\nActing Director\u003Cbr>\nOHT3: Office of GastroRenal, ObGyn,\u003Cbr>\nGeneral Hospital and Urology Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Cc:\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Official correspondent:\u003C\u002Fstrong>\u003Cbr>\nCai Xiaotian at \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>US Agent:\u003C\u002Fstrong>\u003Cbr>\nCharles Mack\u003Cbr>\nIRC USA\u003Cbr>\n2950 E Lindrick Dr\u003Cbr>\nChandler, AZ, US 85249\u003Cbr>\nEmail: \u003Cstrong>(b)(4)\u003C\u002Fstrong> or&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nLiqun Yang\n\nRecipient Title\n\nGeneral Manager\n\nJiangsu Shenli Medical Production Co., Ltd.\n\nNo. 20 Changzheng Road\n\nZhengluzhen\n\nWujin Qu\n\nChangzhou Shi\n\nJiangsu Sheng,\n\nChina\n\n(b)(4)\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\n\nCMS # 677753\n\nMarch 11, 2024\n\nDear Mr. Yang,\n\nThe United States Food and Drug Administration (FDA) has learned that your firm is marketing Jiangsu Shenli Medical Production Co. Ltd. piston syringes of the sizes and configurations listed in Table 1 below in the United States without marketing clearance or approval, in violation of the Federal Food, Drug, and Cosmetic Act (the Act).\n\nModel #\n\nItem Description\n\nModel #\n\nItem Description\n\n83077\n\nSYR 30ML L\u002FS\n\n91839\n\nSYR 20ML L\u002FL YELLOW\n\n83078\n\nSYR 30ML L\u002FL\n\n91840\n\nSYR 3ML L\u002FL PURPLE\n\n83079\n\nSYR 60ML L\u002FS\n\n91841\n\nSYR 5ML L\u002FL PURPLE\n\n83080\n\nSYR 60ML L\u002FL\n\n91842\n\nSYR 10ML L\u002FL PURPLE\n\n83081\n\nSYR 10ML L\u002FS\n\n91845\n\nSYR 20ML L\u002FL BLUE SALINE\n\n83082\n\nSYR 10ML L\u002FL\n\n91846\n\nSYR 10ML L\u002FL YELLOW CONT\n\n83083\n\nSYR 3ML L\u002FS\n\n91847\n\nSYR 10ML L\u002FL BLUE LIDO\n\n83084\n\nSYR 3ML L\u002FL\n\n91849\n\nSYR 10ML L\u002FL BLUE SALINE\n\n83085\n\nSYR 5ML L\u002FS\n\n91850\n\nSYR 10ML L\u002FL RED LIDO\n\n83087\n\nSYR 20ML L\u002FS\n\n91851\n\nSYR 10ML L\u002FL RED HEPARIN\n\n83088\n\nSYR 20ML L\u002FL\n\n91852\n\nSYR 5ML L\u002FL YELLOW NITRO\n\n83089\n\nSYR 1ML TB\n\n91854\n\nSYR 10ML L\u002FL YELLOW LIDO\n\n91820\n\nSYR 3ML L\u002FL RED\n\n91855\n\nSYR 10ML L\u002FL YELLOW HEP\u002FSALINE\n\n91821\n\nSYR 3ML L\u002FL GREEN\n\n91856\n\nSYR 10ML L\u002FL RED CONT\n\n91822\n\nSYR 3ML L\u002FL BLUE\n\n91857\n\nSYR 10ML L\u002FL GREEN CONT\n\n91825\n\nSYR 5ML L\u002FL RED\n\n91858\n\nSYR 20ML L\u002FL WHITE SALINE\n\n91826\n\nSYR 5ML L\u002FL GREEN\n\n91859\n\nSYR 5ML L\u002FL PURPLE NITRO\n\n91827\n\nSYR 5ML L\u002FL BLUE\n\n91863\n\nSYR 20ML L\u002FL YELLOW LIDO\n\n91828\n\nSYR 5ML L\u002FL WHITE\n\n91866\n\nSYR 5ML L\u002FL RED NITRO\n\n91829\n\nSYR 5ML L\u002FL YELLOW\n\n91867\n\nSYR 5ML L\u002FL BLUE HEPARIN\n\n91830\n\nSYR 10ML L\u002FL RED\n\n91872\n\nSYR 10ML L\u002FS BLUE\n\n91831\n\nSYR 10ML L\u002FL GREEN\n\n91873\n\nSYR 10ML L\u002FL WHITE LIDO\n\n91832\n\nSYR 10ML L\u002FL BLUE\n\n91874\n\nSYR 10ML L\u002FS RED\n\n91833\n\nSYR 10ML L\u002FL WHITE\n\n91876\n\nSYR CNTRL 10ML L\u002FL YEL 1\n\n91834\n\nSYR 10ML L\u002FL YELLOW\n\n91877\n\nSYR CNTRL 10ML L\u002FIL YELLOW LIDO\n\n91835\n\nSYR 20ML L\u002FL RED\n\n91878\n\nSYR CNTRL 10 ML L\u002FL RED\n\n91836\n\nSYR 20ML L\u002FL GREEN\n\n91879\n\nSYR CNTRL 10ML L\u002FL GRN\n\n91837\n\nSYR 20ML L\u002FL BLUE\n\n91880\n\nSYR CNTRL 10ML L\u002FL BLUE\n\n91838\n\nSYR 20ML L\u002FL WHITE\n\n91881\n\nSYR 10ML L\u002FL CONTROL\n\nTable 1. List of Jiangsu Shenli Medical Production Co. Ltd. piston syringe configurations implicated in this Warning Letter.\n\nUnder section 201(h) of the Act, 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nFDA has determined, based on information provided by your firm and information available on the Agency's public databases, that the Jiangsu Shenli Medical Production Co. Ltd. piston syringes configurations listed in Table 1 are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(0(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). The devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution these devices with (1) major changes or modifications to the intended use, and\u002For (2) a change or modification in the device that could significantly affect the safety or effectiveness of the device without submitting a premarket notification to FDA as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3)(i)-(ii).\n\nSpecifically, the Jiangsu Shenli Medical Production Co. Ltd. Piston Syringe (5cc Luer Lock) was cleared under K103830 with the following indications for use: The intended use of the Jiangsu Shenli Medical Production Co., Ltd. 5cc luer lock piston syringe is to inject fluids into or withdraw fluids from the body. Based on FDA's evaluation of your firm's activities, there is evidence that your firm is engaged in the distribution of syringes for use within the United States with substantially different technological characteristics, namely sizes other than 5 mL, luer slip instead of luer lock tips, syringes intended for specific drugs, different colors (i.e., colorants), and control syringes, each of which constitute a significant change or modification in design that could significantly alter the safety or effectiveness of the device. For further explanation on the need for a new premarket notification, or \"510(k),\" for changes to the intended use or design affecting safety and effectiveness, it is recommended you consult the guidance document \"Deciding When to Submit a 510(k) for a Change to an Existing Device — Guidance for Industry and Food and Drug Administration Staff (fda.gov).\" In the guidance at Figure 3 — Flowchart B: Technology, Engineering, and Performance Changes, FDA explains why changes in size, color, specific drug indications and connector type all constitute a major change or modification to the device's intended use, for which your firm lacks clearance or approval.\n\nAs discussed above the products listed in Table 1 are misbranded because you made one or more change(s) or modification(s) to each device that could significantly affect the safety or effectiveness of the device without submitting a 510(k) to FDA. Specifically, changing the volume of the syringe, switching from a luer lock to a luer slip syringe tip, and changing from a traditional syringe to a control syringe could result in the risk of patient harm such as inaccurate dosing, a leaking device, a higher risk of inappropriate needle detachment, and incorrect device handling. Furthermore, the addition of color additives to your syringe could result in adverse health effects such as allergic reactions, skin irritation or inflammation, pain, fever, red blood cell damage that induces organ stress, and toxicity that leads to loss of organ function or failure. Labeling the syringe for a specific drug can also cause harm because differences in drug viscosities impact the function of the syringe and can result in patient harm such as inaccurate dosing or incorrect drug usage.\n\nYour firm's failure to submit 510(k)s for these devices has prevented FDA from evaluating the risks posed by these substantially different technological characteristics or from determining that there is reasonable assurance of the safety and effectiveness of these modified devices such that they may be legally marketed syringes. Further, FDA has observed evidence of postmarket safety signals indicating product quality issues that have the potential to cause serious patient harm. Specifically, FDA is aware of multiple customer complaints regarding quality issues (e.g. cracks, breakage during use) for syringes in surgical kits supplied by Jiangsu Shenli Medical Production Co. Ltd.\n\nFor a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\n\nFDA requests that Jiangsu Shenli Medical Production Factory cease any activities that result in the misbranding or adulteration of all the Jiangsu Shenli Medical Production Co. Ltd. piston syringe configurations listed in Table 1, such as the commercial distribution of the device sizes, configurations, and uses discussed above, including selling to initial importers, distributors, or other third parties for distribution and use within the United States or otherwise representing these devices to have the requisite clearance or authorization for marketing in the United States.\n\nGiven the serious nature of the violations of the Act and growing evidence of potential harm, all the Jiangsu Shenli Medical Production Co. Ltd. piston syringes configurations listed in Table 1 are subject to refusal of admission under section 801(a) of the Act, 21 U.S.C. § 381(a), in that they appear to be adulterated. As a result, FDA is taking steps to refuse entry of these devices into the United States, until these violations are addressed.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) your firm has taken. If your firm's planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm's response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm's response should be sent by email to CDRHWamingLetterResponses@fda.hhs.gov or by mail to:\n\nFood and Drug Administration\n\nCenter for Devices and Radiological Health\n\nOffice of Regulatory Programs\n\nDivision of Regulatory Programs 2: Establishment Support\n\nRegulatory Inspections and Audits Team\n\nWhite Oak Building 66\n\n10903 New Hampshire Ave.\n\nSilver Spring, MD 20993\n\nRefer to the identification number CMS # 677753 when replying. We remind you that only written communication is considered as official. If you have any questions about the contents of this letter, please contact: Shruti Misty at Shruti.Mistry@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm. It is your firm's responsibility to ensure compliance with the applicable laws and regulations administered by FDA.\n\nSincerely yours,\n\n\u002FS\u002F\n\nKellie B. Kelm, Ph.D.\n\nActing Director\n\nOHT3: Office of GastroRenal, ObGyn,\n\nGeneral Hospital and Urology Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCc:\n\nOfficial correspondent:\n\nCai Xiaotian at (b)(4)\n\nUS Agent:\n\nCharles Mack\n\nIRC USA\n\n2950 E Lindrick Dr\n\nChandler, AZ, US 85249\n\nEmail: (b)(4) or (b)(4)","jiangsu-shenli-medical-production-co-ltd-677753-03182024","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fjiangsu-shenli-medical-production-co-ltd-677753-03182024","2026-10-26T08:09:04.125701+00:00","2024-03-19","677753","2026-08-20T00:13:56.316+00:00","2024-03-18",{"id":109,"raw":110,"subject":115,"body_html":116,"body_text":117,"firm_name":118,"letter_id":119,"created_at":120,"fei_number":19,"letter_url":121,"updated_at":122,"action_type":22,"case_status":23,"posted_date":123,"marcs_cms_no":124,"product_type":48,"closeout_date":19,"issuing_office":114,"recipient_name":125,"body_fetched_at":126,"delivery_method":127,"recipient_title":19,"reference_number":19,"action_taken_date":128,"medical_device_id":19,"response_letter_date":19},3352,[111,112,113,114,115,13,13,13],"\u003Ctime datetime=\"2021-05-18T13:20:00Z\">05\u002F18\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-04-21T04:00:00Z\">04\u002F21\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorth-american-hirudin-biotech-products-inc-613103-04212021\">North American Hirudin Biotech Products Inc.\u003C\u002Fa>","Office of Regulatory Affairs","New Drug\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Overnight Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Zengxun An\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>North American Hirudin Biotech Products Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2531 Broadway, Suite A\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Everett\u003C\u002Fspan>, \u003Cspan>WA\u003C\u002Fspan> \u003Cspan>98201\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Regulatory Affairs\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>April 21, 2021\u003C\u002Fp>\n\n\u003Cp>In reply, refer to CMS 613103\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. An:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address http:\u002F\u002Fushirudin.com\u002F in February and April 2021, and has determined that you take orders there for your products “Hirudin” and “Red 65”. We also reviewed your websites at http:\u002F\u002Fwww.naturalhirudin.com\u002F and http:\u002F\u002Fbuyred65.com\u002F, both of which contain links to http:\u002F\u002Fushirudin.com\u002F where the products can be purchased. The claims on your websites establish that the products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Hirudin\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the http:\u002F\u002Fushirudin.com\u002F website:\u003Cbr>\n• “Blood-thinning: Hirudin is a Natural Blood Thinner . . . help normalize the blood sugar level in your blood”\u003C\u002Fp>\n\n\u003Cp>• “Hirudin . . . has unique abilities to . . . dissolve the . . . cholesterol in your blood so your blood flows unrestricted.”\u003C\u002Fp>\n\n\u003Cp>• “[S]trengthens your body’s defense capability against common viruses and bacteria.”\u003C\u002Fp>\n\n\u003Cp>• “Is hirudin a potential therapeutic agent for arthritis?”\u003C\u002Fp>\n\n\u003Cp>• “[H]irudin . . . are alternatives to heparin for the treatment of: 1) unstable angina, 2) abrupt closure and restenosis following coronary angioplasty, and 3) prevention of deep vein thrombosis after major orthopedic surgery . . . They are fast becoming the drugs of choice for the anticoagulant treatment of patients with heparin-induced thrombocytopenia with thromboembolic complications.”\u003C\u002Fp>\n\n\u003Cp>On the website http:\u002F\u002Fwww.naturalhirudin.com\u002F:\u003Cbr>\n• “Hirudin has been scientifically proven to be the most potent anti-coagulant.”\u003C\u002Fp>\n\n\u003Cp>• “Hirudin is . . . the most effective natural anticoagulant. Hirudin has been hailed as the promising molecule in the fight against cardiovascular and blood-related disease.”\u003C\u002Fp>\n\n\u003Cp>• “Hirudin Tablet is based on . . . its powers in promoting blood-thinning . . ..”\u003C\u002Fp>\n\n\u003Cp>• “In the early days of the twentieth century, medical pioneers used leeches to treat cardiovascular disease primarily due to the natural anticoagulant, hirudin . . . Hirudin has a system wide anticoagulation effect . . . mechanisms that contribute to the treatment of cardiovascular diseases or conditions such as a stroke or a heart attack.”\u003C\u002Fp>\n\n\u003Cp>On the webpage for your Hirudin product at http:\u002F\u002Fushirudin.com\u002Fhirudin-the-original-formula\u002F:\u003Cbr>\n• “Hirudin has been recognized by scientists and medical professionals alike as the most effective natural anticoagulant. Hirudin has been hailed . . . in the fight against cardiovascular and blood-related disease.”\u003C\u002Fp>\n\n\u003Cp>• “Hirudin Tablet is based. . . its powers in promoting blood-thinning . . ..”\u003C\u002Fp>\n\n\u003Cp>• “Benefits of Hirudin Tablet:\u003Cbr>\n&nbsp; &nbsp; o [N]aturally lowers cholesterol content from your blood system.\u003Cbr>\n&nbsp; &nbsp; o Blood-thinning . . . help normalize the blood sugar level in your blood.\u003Cbr>\n&nbsp; &nbsp; o [D]issolve the . . . cholesterol in your blood . . .\u003Cbr>\n&nbsp; &nbsp; o [S]trengthens your body’s defense capability against common viruses and bacteria.”\u003Cbr>\n\u003Cbr>\n\u003Cstrong>Red 65\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the website http:\u002F\u002Fbuyred65.com\u002F:\u003Cbr>\n• “Red 65 blood cleanser for better heart health natural blood thinner natural lower cholesteral [sic] and natural prevent diabetes”\u003C\u002Fp>\n\n\u003Cp>• “[N]aturally lowers cholesterol content from your blood system.”\u003C\u002Fp>\n\n\u003Cp>• “Blood-thinning . . . help normalize the blood sugar level in your blood.”\u003C\u002Fp>\n\n\u003Cp>• “[S]trengthens your body’s defense capability against common viruses and bacteria.”\u003C\u002Fp>\n\n\u003Cp>• “RED65 Offers Amazing Results for . . . Pain Relief . . . Anticoagulation - Binds Itself to Thrombins, Inhibiting Coagulation, Dissolving Existing Blood Clots . . . Blood Thinner . . . a Potent Anti-Coagulant that Thins the Blood . . . Vasodilator - Widens Vessel Walls . . .”\u003C\u002Fp>\n\n\u003Cp>• “Hirudin [an ingredient in Red 65] has been scientifically proven to be the most potent anti-coagulant.”\u003C\u002Fp>\n\n\u003Cp>On the webpage for your Red 65 product at http:\u002F\u002Fushirudin.com\u002Fred-65-natural-blood-thinner\u002F:\u003Cbr>\n• “North American Hirudin Red 65 a Natural Blood Thinner . . .”\u003C\u002Fp>\n\n\u003Cp>• “Red 65 is a natural blood thinner . . . Hirudin has been recognized by scientists and medical professionals alike as the most effective natural anticoagulant. Hirudin has been hailed . . . in the fight against cardiovascular and blood-related disease.”\u003C\u002Fp>\n\n\u003Cp>• “. . . Red 65 is based on . . . its powers in promoting blood-thinning . . ..”\u003C\u002Fp>\n\n\u003Cp>• “Benefits of Red 65:\u003Cbr>\n&nbsp; &nbsp; o Blood-thinning . . . help normalize the blood sugar level in your blood. Some diabetic patients have reported that Red65 is a natural diabetes control. Others have described Red65 as a natural Coumadin . . .\u003Cbr>\n&nbsp; &nbsp; o [D]issolve . . . cholesterol in your blood. . .\u003Cbr>\n&nbsp; &nbsp; o [S]trengthens your body’s defense capability against common viruses and bacteria.”\u003Cbr>\n\u003Cbr>\nOn the webpage titled “HOW DOES HIRUDIN DETOXIFY OUR BODIES?” at http:\u002F\u002Fushirudin.com\u002Fhow-does-hirudin-detoxify-our-bodies-2\u002F, which contains links to purchase Hirudin and Red 65 products:\u003Cbr>\n• “In the early days of the twentieth century, medical pioneers used leeches to treat cardiovascular disease primarily due to the natural anticoagulant, hirudin. Hirudin has . . . mechanisms that contribute to the treatment of cardiovascular diseases or conditions such as a stroke or a heart attack.”\u003C\u002Fp>\n\n\u003Cp>• “. . . hirudin specifically targets, prevents and dissolves the formation of clots . . . It is commonly used to treat other blood coagulation disorders, skin hematomas, and superficial varicose veins.”\u003C\u002Fp>\n\n\u003Cp>On the webpage titled “WHAT IS HIRUDIN AND WHAT DOES IT DO?” at http:\u002F\u002Fushirudin.com\u002Fwhat-is-hirudin-and-what-does-it-do\u002F, which contains links to purchase Hirudin and Red 65 products:\u003Cbr>\n• “Since 1853 Hirudin has been recognized by scientists and medical professionals alike as the most effective natural anticoagulant. Hirudin has been hailed . . . in the fight against cardiovascular and blood-related disease.”\u003C\u002Fp>\n\n\u003Cp>• “Hirudin Tablet is based on . . . its powers in promoting blood-thinning.”\u003C\u002Fp>\n\n\u003Cp>On the webpage titled “THE TABLET” at http:\u002F\u002Fushirudin.com\u002Fthe-tablet\u002F, which contains links to purchase Hirudin and Red 65 products:\u003Cbr>\n• “Hirudin has long been established in medical literature and research as a beneficial anticoagulant treatment . . ..”\u003C\u002Fp>\n\n\u003Cp>• “Hirudin supplement tablet is . . . helping to maintain a normal blood pressure and blood sugar level which lowers the risk of developing cardiovascular and cerebrovascular diseases.”\u003C\u002Fp>\n\n\u003Cp>On the webpage titled: “Hirudin Evolution” at http:\u002F\u002Fushirudin.com\u002Fhirudin-evolution\u002F, which contains links to purchase Hirudin and Red65 products:\u003Cbr>\n• “Thrombosis is a major cause of death and disability from myocardial infarction, stroke, peripheral ischemia, and pulmonary embolism.”\u003C\u002Fp>\n\n\u003Cp>• “Hirudin is the most potent non-covalent inhibitor of thrombin.”\u003C\u002Fp>\n\n\u003Cp>• “[Hirudin and synthetic analogues of hirudin] are alternatives to heparin for the treatment of: 1) unstable angina, 2) abrupt closure and restenosis following coronary angioplasty, and 3) prevention of deep vein thrombosis after major orthopedic surgery. They are also used as adjunct to fibrinolytic therapy. They are fast becoming the drugs of choice for the anticoagulant treatment of patients with heparin-induced thrombocytopenia with thromboembolic complications.”\u003C\u002Fp>\n\n\u003Cp>Your “Hirudin” and “Red 65” products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. § 331(d) and § 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your “Hirudin” and “Red 65” products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, “Hirudin” and “Red 65” products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to the Food and Drug Administration, Attention: Jinkee M. Vila-Binayug, Compliance Officer, 22215 26th Avenue SE, Suite 210, Bothell, Washington 98021-4421. If you have any questions regarding this letter, please contact Compliance Officer Vila-Binayug at 425-302-0413.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Miriam R. Burbach\u003Cbr>\nDistrict Director\u003Cbr>\nProgram Division Director\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nOvernight Delivery\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nZengxun An\n\nRecipient Title\n\nPresident\n\nNorth American Hirudin Biotech Products Inc.\n\n2531 Broadway, Suite A\n\nEverett, WA 98201\n\nUnited States\n\nIssuing Office:\n\nOffice of Regulatory Affairs\n\nUnited States\n\nApril 21, 2021\n\nIn reply, refer to CMS 613103\n\nWARNING LETTER\n\nDear Mr. An:\n\nThis is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address http:\u002F\u002Fushirudin.com\u002F in February and April 2021, and has determined that you take orders there for your products “Hirudin” and “Red 65”. We also reviewed your websites at http:\u002F\u002Fwww.naturalhirudin.com\u002F and http:\u002F\u002Fbuyred65.com\u002F, both of which contain links to http:\u002F\u002Fushirudin.com\u002F where the products can be purchased. The claims on your websites establish that the products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that your products are intended for use as drugs include:\n\nHirudin\n\nOn the http:\u002F\u002Fushirudin.com\u002F website:\n\n• “Blood-thinning: Hirudin is a Natural Blood Thinner . . . help normalize the blood sugar level in your blood”\n\n• “Hirudin . . . has unique abilities to . . . dissolve the . . . cholesterol in your blood so your blood flows unrestricted.”\n\n• “[S]trengthens your body’s defense capability against common viruses and bacteria.”\n\n• “Is hirudin a potential therapeutic agent for arthritis?”\n\n• “[H]irudin . . . are alternatives to heparin for the treatment of: 1) unstable angina, 2) abrupt closure and restenosis following coronary angioplasty, and 3) prevention of deep vein thrombosis after major orthopedic surgery . . . They are fast becoming the drugs of choice for the anticoagulant treatment of patients with heparin-induced thrombocytopenia with thromboembolic complications.”\n\nOn the website http:\u002F\u002Fwww.naturalhirudin.com\u002F:\n\n• “Hirudin has been scientifically proven to be the most potent anti-coagulant.”\n\n• “Hirudin is . . . the most effective natural anticoagulant. Hirudin has been hailed as the promising molecule in the fight against cardiovascular and blood-related disease.”\n\n• “Hirudin Tablet is based on . . . its powers in promoting blood-thinning . . ..”\n\n• “In the early days of the twentieth century, medical pioneers used leeches to treat cardiovascular disease primarily due to the natural anticoagulant, hirudin . . . Hirudin has a system wide anticoagulation effect . . . mechanisms that contribute to the treatment of cardiovascular diseases or conditions such as a stroke or a heart attack.”\n\nOn the webpage for your Hirudin product at http:\u002F\u002Fushirudin.com\u002Fhirudin-the-original-formula\u002F:\n\n• “Hirudin has been recognized by scientists and medical professionals alike as the most effective natural anticoagulant. Hirudin has been hailed . . . in the fight against cardiovascular and blood-related disease.”\n\n• “Hirudin Tablet is based. . . its powers in promoting blood-thinning . . ..”\n\n• “Benefits of Hirudin Tablet:\n\no [N]aturally lowers cholesterol content from your blood system.\n\no Blood-thinning . . . help normalize the blood sugar level in your blood.\n\no [D]issolve the . . . cholesterol in your blood . . .\n\no [S]trengthens your body’s defense capability against common viruses and bacteria.”\n\nRed 65\n\nOn the website http:\u002F\u002Fbuyred65.com\u002F:\n\n• “Red 65 blood cleanser for better heart health natural blood thinner natural lower cholesteral [sic] and natural prevent diabetes”\n\n• “[N]aturally lowers cholesterol content from your blood system.”\n\n• “Blood-thinning . . . help normalize the blood sugar level in your blood.”\n\n• “[S]trengthens your body’s defense capability against common viruses and bacteria.”\n\n• “RED65 Offers Amazing Results for . . . Pain Relief . . . Anticoagulation - Binds Itself to Thrombins, Inhibiting Coagulation, Dissolving Existing Blood Clots . . . Blood Thinner . . . a Potent Anti-Coagulant that Thins the Blood . . . Vasodilator - Widens Vessel Walls . . .”\n\n• “Hirudin [an ingredient in Red 65] has been scientifically proven to be the most potent anti-coagulant.”\n\nOn the webpage for your Red 65 product at http:\u002F\u002Fushirudin.com\u002Fred-65-natural-blood-thinner\u002F:\n\n• “North American Hirudin Red 65 a Natural Blood Thinner . . .”\n\n• “Red 65 is a natural blood thinner . . . Hirudin has been recognized by scientists and medical professionals alike as the most effective natural anticoagulant. Hirudin has been hailed . . . in the fight against cardiovascular and blood-related disease.”\n\n• “. . . Red 65 is based on . . . its powers in promoting blood-thinning . . ..”\n\n• “Benefits of Red 65:\n\no Blood-thinning . . . help normalize the blood sugar level in your blood. Some diabetic patients have reported that Red65 is a natural diabetes control. Others have described Red65 as a natural Coumadin . . .\n\no [D]issolve . . . cholesterol in your blood. . .\n\no [S]trengthens your body’s defense capability against common viruses and bacteria.”\n\nOn the webpage titled “HOW DOES HIRUDIN DETOXIFY OUR BODIES?” at http:\u002F\u002Fushirudin.com\u002Fhow-does-hirudin-detoxify-our-bodies-2\u002F, which contains links to purchase Hirudin and Red 65 products:\n\n• “In the early days of the twentieth century, medical pioneers used leeches to treat cardiovascular disease primarily due to the natural anticoagulant, hirudin. Hirudin has . . . mechanisms that contribute to the treatment of cardiovascular diseases or conditions such as a stroke or a heart attack.”\n\n• “. . . hirudin specifically targets, prevents and dissolves the formation of clots . . . It is commonly used to treat other blood coagulation disorders, skin hematomas, and superficial varicose veins.”\n\nOn the webpage titled “WHAT IS HIRUDIN AND WHAT DOES IT DO?” at http:\u002F\u002Fushirudin.com\u002Fwhat-is-hirudin-and-what-does-it-do\u002F, which contains links to purchase Hirudin and Red 65 products:\n\n• “Since 1853 Hirudin has been recognized by scientists and medical professionals alike as the most effective natural anticoagulant. Hirudin has been hailed . . . in the fight against cardiovascular and blood-related disease.”\n\n• “Hirudin Tablet is based on . . . its powers in promoting blood-thinning.”\n\nOn the webpage titled “THE TABLET” at http:\u002F\u002Fushirudin.com\u002Fthe-tablet\u002F, which contains links to purchase Hirudin and Red 65 products:\n\n• “Hirudin has long been established in medical literature and research as a beneficial anticoagulant treatment . . ..”\n\n• “Hirudin supplement tablet is . . . helping to maintain a normal blood pressure and blood sugar level which lowers the risk of developing cardiovascular and cerebrovascular diseases.”\n\nOn the webpage titled: “Hirudin Evolution” at http:\u002F\u002Fushirudin.com\u002Fhirudin-evolution\u002F, which contains links to purchase Hirudin and Red65 products:\n\n• “Thrombosis is a major cause of death and disability from myocardial infarction, stroke, peripheral ischemia, and pulmonary embolism.”\n\n• “Hirudin is the most potent non-covalent inhibitor of thrombin.”\n\n• “[Hirudin and synthetic analogues of hirudin] are alternatives to heparin for the treatment of: 1) unstable angina, 2) abrupt closure and restenosis following coronary angioplasty, and 3) prevention of deep vein thrombosis after major orthopedic surgery. They are also used as adjunct to fibrinolytic therapy. They are fast becoming the drugs of choice for the anticoagulant treatment of patients with heparin-induced thrombocytopenia with thromboembolic complications.”\n\nYour “Hirudin” and “Red 65” products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. § 331(d) and § 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour “Hirudin” and “Red 65” products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, “Hirudin” and “Red 65” products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action, including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nPlease send your reply to the Food and Drug Administration, Attention: Jinkee M. Vila-Binayug, Compliance Officer, 22215 26th Avenue SE, Suite 210, Bothell, Washington 98021-4421. If you have any questions regarding this letter, please contact Compliance Officer Vila-Binayug at 425-302-0413.\n\nSincerely,\n\n\u002FS\u002F\n\nMiriam R. Burbach\n\nDistrict Director\n\nProgram Division Director","North American Hirudin Biotech Products Inc.","north-american-hirudin-biotech-products-inc-613103-04212021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorth-american-hirudin-biotech-products-inc-613103-04212021","2026-10-26T08:09:34.567247+00:00","2021-05-18","613103","Zengxun An","2026-08-20T03:08:12.347+00:00","Overnight Delivery","2021-04-21",{"id":130,"raw":131,"subject":136,"body_html":137,"body_text":138,"firm_name":139,"letter_id":140,"created_at":84,"fei_number":19,"letter_url":141,"updated_at":142,"action_type":22,"case_status":23,"posted_date":143,"marcs_cms_no":144,"product_type":145,"closeout_date":19,"issuing_office":135,"recipient_name":146,"body_fetched_at":147,"delivery_method":29,"recipient_title":19,"reference_number":148,"action_taken_date":143,"medical_device_id":19,"response_letter_date":19},1185,[132,133,134,135,136,13,13,13],"\u003Ctime datetime=\"2024-10-30T15:00:00Z\">10\u002F30\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-10-30T04:00:00Z\">10\u002F30\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbfl-metal-products-co-ltd-695371-10302024\">BFL Metal Products Co., LTD\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>RW2402224\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Liang Lihong\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>BFL Metal Products Co., LTD\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Guangdong Sheng\u003C\u002Fspan>,\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Lily@dallltd.com\"> Lily@dallltd.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:sales@qr-joy.com\"> sales@qr-joy.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 30, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Liang Lihong:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Ffumevapors.com and determined that electronic nicotine delivery system (ENDS) products listed there are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobaccoproducts\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacturer and offer for sale or distribution to customers in the United States ENDS products that lack a marketing authorization order: WeFume Vape 30K Puffs – Lychee Soda and WeFume Vape 30K Puffs – Apple Pineapple.\u003C\u002Fp>\n\n\u003Cp>The tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Additional Considerations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA finds these products particularly concerning because the product labeling and\u002For advertising for WeFume Vape 30K Puffs (see Exhibit A) may be attractive to youth by imitating a smartphone or other smart technology (see Exhibit B).\u003C\u002Fp>\n\n\u003Cdiv>  \u003Cimg src=\"https:\u002F\u002Fwww.fda.gov\u002Ffiles\u002F695371-BFL_0.png\" alt=\"695371-Watchface\">\n\n\u003C\u002Fdiv>\n\n\n\u003Cp>In particular, youth and young adults may be attracted to the products’ design and functionalities imitating smart phones and other smart technology, including:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Featuring customizable settings, Bluetooth connectivity, and access to 16 different apps like calls, music, and voice assistants”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Further, the products’ design may be attractive to youth because the design helps conceal the nature of the product as a tobacco product from parents, teachers, or other adults, and therefore could be openly carried without revealing to parents, teachers, or other adults that the products are tobacco products. FDA is concerned about the youth appeal and widespread youth use of ENDS products, which are the most common tobacco products used by students reporting current tobacco use Any efforts to entice youth to use tobacco products are of concern to FDA. Sales of such unauthorized products are prohibited, and FDA is concerned that your actions likely encourage unlawful sales, maintain or increase youth use, and contribute to the public health and safety concerns associated with ENDS products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>For a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketingorders#PMTAView%20all%20marketing%20granted.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to adequately address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, and take any necessary actions to bring these tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2402224, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>John E. Verbeten\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>VIA UPS and Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>Fume\u003Cbr>\n1210 Stirling Rd Unit 10B\u003Cbr>\nHollywood, FL 33004\u003Cbr>\ninfo@fume.com\u003Cbr>\nsupport@fume.com\u003C\u002Fp>\n\n\u003Cp>QR Joy Inc\u003Cbr>\nAttn: Shlomi Evgi and Yogev Shvo\u003Cbr>\n8570 Stirling Rd Suite 102\u003Cbr>\nHollywood, FL 33024\u003C\u002Fp>\n\n\u003Cp>QR Joy Inc.\u003Cbr>\n1790 SW 30th Ave\u003Cbr>\nHallandale, FL 33009\u003C\u002Fp>\n\n\u003Cp>QR Joy Inc.\u003Cbr>\n425 NW 10th Terrace\u003Cbr>\nHallandale Beach, Florida 33009\u003Cbr>\ninfo@qr-joy.com\u003C\u002Fp>\n\n\u003Cp>Alibaba Cloud Computing (Beijing) Co., Ltd.\u003Cbr>\nDomainAbuse@service.aliyun.com\u003C\u002Fp>\n\n\u003Cp>Hostinger International Ltd.\u003Cbr>\nnre@hostinger.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nReference #:\n\nRW2402224\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nLiang Lihong\n\nBFL Metal Products Co., LTD\n\nGuangdong Sheng,\n\nChina\n\nLily@dallltd.com\n\nsales@qr-joy.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nOctober 30, 2024\n\nWARNING LETTER\n\nDear Liang Lihong:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Ffumevapors.com and determined that electronic nicotine delivery system (ENDS) products listed there are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobaccoproducts\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\n\nFDA has determined that you manufacturer and offer for sale or distribution to customers in the United States ENDS products that lack a marketing authorization order: WeFume Vape 30K Puffs – Lychee Soda and WeFume Vape 30K Puffs – Apple Pineapple.\n\nThe tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)).\n\nAdditional Considerations\n\nFDA finds these products particularly concerning because the product labeling and\u002For advertising for WeFume Vape 30K Puffs (see Exhibit A) may be attractive to youth by imitating a smartphone or other smart technology (see Exhibit B).\n\nIn particular, youth and young adults may be attracted to the products’ design and functionalities imitating smart phones and other smart technology, including:\n\n“Featuring customizable settings, Bluetooth connectivity, and access to 16 different apps like calls, music, and voice assistants”\n\nFurther, the products’ design may be attractive to youth because the design helps conceal the nature of the product as a tobacco product from parents, teachers, or other adults, and therefore could be openly carried without revealing to parents, teachers, or other adults that the products are tobacco products. FDA is concerned about the youth appeal and widespread youth use of ENDS products, which are the most common tobacco products used by students reporting current tobacco use Any efforts to entice youth to use tobacco products are of concern to FDA. Sales of such unauthorized products are prohibited, and FDA is concerned that your actions likely encourage unlawful sales, maintain or increase youth use, and contribute to the public health and safety concerns associated with ENDS products.\n\nConclusion and Requested Actions\n\nFDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\n\nFor a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketingorders#PMTAView%20all%20marketing%20granted.\n\nIt is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to adequately address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, and take any necessary actions to bring these tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2402224, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nJohn E. Verbeten\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA UPS and Electronic Mail\n\ncc:\n\nFume\n\n1210 Stirling Rd Unit 10B\n\nHollywood, FL 33004\n\ninfo@fume.com\n\nsupport@fume.com\n\nQR Joy Inc\n\nAttn: Shlomi Evgi and Yogev Shvo\n\n8570 Stirling Rd Suite 102\n\nHollywood, FL 33024\n\nQR Joy Inc.\n\n1790 SW 30th Ave\n\nHallandale, FL 33009\n\nQR Joy Inc.\n\n425 NW 10th Terrace\n\nHallandale Beach, Florida 33009\n\ninfo@qr-joy.com\n\nAlibaba Cloud Computing (Beijing) Co., Ltd.\n\nDomainAbuse@service.aliyun.com\n\nHostinger International Ltd.\n\nnre@hostinger.com","BFL Metal Products Co., LTD","bfl-metal-products-co-ltd-695371-10302024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbfl-metal-products-co-ltd-695371-10302024","2026-10-26T08:08:03.9974+00:00","2024-10-30","695371","Tobacco","Liang Lihong","2026-08-19T20:15:46.236+00:00","RW2402224",{"id":150,"raw":151,"subject":156,"body_html":158,"body_text":159,"firm_name":160,"letter_id":161,"created_at":64,"fei_number":19,"letter_url":162,"updated_at":163,"action_type":22,"case_status":67,"posted_date":164,"marcs_cms_no":165,"product_type":166,"closeout_date":167,"issuing_office":155,"recipient_name":168,"body_fetched_at":169,"delivery_method":170,"recipient_title":19,"reference_number":19,"action_taken_date":171,"medical_device_id":19,"response_letter_date":19},2792,[152,153,154,155,156,13,157,13],"\u003Ctime datetime=\"2022-03-29T13:20:00Z\">03\u002F29\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-03-04T05:00:00Z\">03\u002F04\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedina-baking-and-powder-products-inc-619373-03042022\">Medina Baking and Powder Products, Inc.\u003C\u002Fa>","Office of Human and Animal Food Operations Division IV East","Food Labeling\u002FMisbranded","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedina-baking-and-powder-products-inc-619373-01102024\">\u003Ctime datetime=\"2024-01-12T05:00:00Z\">01\u002F12\u002F2024\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Roberto Martin\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Medina Baking and Powder Products, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1864 NW 22 St.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Miami\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33142\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:rmartin@medinabaking.com\"> rmartin@medinabaking.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Human and Animal Food Operations Division IV East\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>March 4, 2022\u003C\u002Fp>\n\n\u003Cp>22-HAFE4-WL-03\u002FCMS No. 619373\u003Cbr>\n\u003Cbr>\nThe United States Food and Drug Administration (FDA) inspected your facility located at 1864 NW 22 St., Miami, FL 33142 from August 31, 2021 to September 14, 2021. Your facility manufactures food products including liquid flavors, marshmallow powder, and ice cream stabilizer. Our inspection focused on liquid food flavors and found serious violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP &amp; PC rule), Title 21, Code of Federal Regulations (CFR), part 117 (21 CFR part 117). At the conclusion of the inspection, FDA issued an FDA Form 483, Inspectional Observations, listing the deviations found at your facility.\u003C\u002Fp>\n\n\u003Cp>Based on FDA’s inspectional findings, we determined that you did not follow the requirements of the CGMP &amp; PC rule. The failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of the CGMP &amp; PC rule (located in subparts A, C, D, E, F, and G of part 117) is prohibited by section 301(uu) of the Act (21 U.S.C. § 331(uu)). Further, during the inspection, you revised your labels to include the allergens and colors used in the production of many of your products; however, several of your products with revised labels (i.e., Medina brand Vanilla Flavor Imitation (White), Artificial Flavor Mantecado, and Marsh-Mallow No. 2 Meringue) remain misbranded within the meaning of section 403 of the Act (21 U.S.C. § 343). You may find the Act and further information about the CGMP &amp; PC rule through links in FDA's home page at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>We received your firm’s written response to the FDA Form 483 dated September 24, 2021, which included a description of your corrective actions taken and planned. After reviewing the inspectional findings and your response to the observations listed in the FDA Form 483, we are issuing this letter to advise you of FDA’s concerns and provide detailed information describing the findings at your facility. We address your response below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Preventive Controls (21 CFR part 117, Subpart C)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You did not identify and evaluate undeclared allergens due to an incorrect label as a known or reasonably foreseeable hazard to determine whether the hazard requires a preventive control in your allergen-containing liquid food flavors, as required by 21 CFR 117.130(a)(1). Specifically, your hazard analysis for “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” did not consider undeclared allergens, but your Vanilla Flavor Imitation (White) and Chocolate Flavor both contain egg (a major food allergen). Foods containing allergens can cause serious adverse health consequences or death to allergic individuals if they consume a food to which they are allergic. A knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify food allergens as hazards requiring a preventive control. Preventive controls for food allergens include procedures, practices, and processes employed for labeling to ensure that all food allergens are included on the label (see 21 CFR 117.135(c)(2)(ii)). You did not have such controls in place as evidenced by your September 9, 2021, recall of your Vanilla Flavor Imitation (White) and Chocolate Flavor products, due in part to undeclared egg. The deficiency was revealed when FDA investigators observed that your Mantecado Flavor contains sugar yolks, which contain egg. Your Mantecado Flavor is used as an ingredient in your Chocolate Flavor, which is used as an ingredient in your Vanilla Flavor Imitation (White). However, until the FDA inspection, you were not declaring the egg allergen on product labels for Vanilla Flavor Imitation (White) or Chocolate Flavor.\u003C\u002Fp>\n\n\u003Cp>In your written response, you stated that your labels for the Vanilla Flavor Imitation (White) and Chocolate Flavor will be updated to include allergens and promised to complete a label review and document the label review for any future products made to ensure compliance. We will review the adequacy of your labeling corrective actions during the next inspection. Your written response did not include a revised hazard analysis or new preventive control procedure to ensure control of the undeclared allergen hazard.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranding\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>1. Your Medina brand Marsh-Mallow No. 2 Meringue product is misbranded within the meaning of section 403(f) of the Act [21 U.S.C. §343(f)] because the label contains statements in Spanish but does not contain an ingredient statement and “contains” statement in Spanish, as required by 21 CFR 101.15(c)(2). Further, your Artificial Flavor Mantecado product is misbranded within the meaning of section 403(f) of the Act because it does not contain a statement of identity in English, as required by 21 CFR 101.15(c)(1).\u003C\u002Fp>\n\n\u003Cp>2. Your Medina brand Vanilla Flavor Imitation (White), Artificial Flavor Mantecado, and Marsh-Mallow No. 2 Meringue products are misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] in that the products are fabricated from two or more ingredients and the common or usual name of each ingredient is not declared on the label, as required by 21 CFR 101.4. Specifically:\u003C\u002Fp>\n\n\u003Cp>a. “Vegetable Gum” and “Gum” are not the common or usual names for these ingredients. We note that the flavor formulations include Xanthan gum and Tragacanth gum; however, the ingredient lists declare “vegetable gum.” There is no provision in 21 CFR 101.4(b) for the generic term “vegetable gum,” nor for the collective listing of gum ingredients. For the Marsh-Mallow No. 2 Meringue product, we note that the ingredient list declares “Tragacanth, Gum”; it is unclear whether this is a typographical error with a misplaced comma or is intended to refer to two ingredients.\u003Cbr>\nb. The labels fail to list some of the ingredients in the formulations. For example, based on the formulations provided, the Medina brand Vanilla Flavor Imitation (White) contains sugar and honey and the Mantecado formulation contains sugar; however, these ingredients are not declared in the respective ingredient lists.\u003Cbr>\nc. The formulations for both flavor products (Medina brand Vanilla Flavor Imitation (White) and the Artificial Flavor Mantecado) include the ingredient “Benzo dihydro pyrone dolcotone.” Based on the photo of the label of this ingredient, the name is Benzodihydropyrone. The Mantecado label declares the ingredient as “dolocotone” and the Vanilla flavor does not declare this specific ingredient. Additional names for this ingredient are found here: \u003Ca href=\"https:\u002F\u002Fwww.cfsanappsexternal.fda.gov\u002Fscripts\u002Ffdcc\u002Findex.cfm?set=FoodSubstances&amp;id=DIHYDROCOUMARIN\">https:\u002F\u002Fwww.cfsanappsexternal.fda.gov\u002Fscripts\u002Ffdcc\u002Findex.cfm?set=FoodSubstances&amp;id=DIHYDROCOUMARIN\u003C\u002Fa>. “Dolocotone” is not an appropriate common or usual name for an ingredient.\u003Cbr>\nd. The formulation for the Marsh-Mallow No. 2 Meringue includes the ingredient “Clearjel,” which is modified corn starch; however, the ingredient label declares “starch,” which is not the appropriate common or usual name for modified corn starch.\u003Cbr>\ne. The ingredients on the Marsh-Mallow No. 2 Meringue label are not declared in descending order of predominance based on the formulation. For example, according to your \u003Cstrong>(b)(4)\u003C\u002Fstrong> record, the amount of salt used in the product is “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” of a bag which weighs \u003Cstrong>(b)(4)\u003C\u002Fstrong> pounds, resulting in \u003Cstrong>(b)(4)\u003C\u002Fstrong> pounds of salt. Your product label lists salt after ingredients such as Ethyl Vanillin and Vanillin which are less than \u003Cstrong>(b)(4)\u003C\u002Fstrong> pounds each in the formulation.\u003C\u002Fp>\n\n\u003Cp>3. Your Artificial Flavor Mantecado product is misbranded within the meaning of section 403(e)(2) of the Act [21 U.S.C. §343(e)(2)] because it fails to bear an accurate statement of the net quantity of contents in terms of weight, measure, or numerical count as required by 21 CFR 101.7. The label includes two different net quantity declarations, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and below that, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”. The net quantity of contents must be accurate; therefore, a label cannot declare two different net quantities.\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure your facility complies with all requirements of federal law, including FDA regulations. You should take prompt action to correct or implement corrections to the violations cited in this letter. Failure to do so may result in legal action without further notice, including, without limitation, seizure, injunction, or administrative action for suspension of food facility registration if criteria and conditions warrant.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Additional comments:\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We note that “Vanillin” is misspelled as “Vainillin” twice on the Mantecado label. We also note that “Latose” on the Marsh-Mallow No. 2 Meringue label likely is intended to refer to “Lactose.”\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of the receipt of this letter, of the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration. If you cannot complete addressing these violations within 15 working days, state the reason for the delay and the timeframe within which you will do so.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to the Food and Drug Administration, attention of: Mr. Ramon A. Hernandez, Program Division Director, 466 Fernandez Juncos Avenue, San Juan, Puerto Rico 00901. If you have questions regarding this letter, please contact Mr. Donald J. Mee, Compliance Officer, at (904) 353-4560 Ext. 114, or via e-mail at donald.mee@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ramon A. Hernandez\u003Cbr>\nDistrict Director, San Juan District Office\u003Cbr>\nProgram Division Director,\u003Cbr>\nOffice of Human and Animal Food Operations\u003Cbr>\nDivision IV East\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nElectronic Mail\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Roberto Martin\n\nRecipient Title\n\nPresident\n\nMedina Baking and Powder Products, Inc.\n\n1864 NW 22 St.\n\nMiami, FL 33142\n\nUnited States\n\nrmartin@medinabaking.com\n\nIssuing Office:\n\nOffice of Human and Animal Food Operations Division IV East\n\nUnited States\n\nWARNING LETTER\n\nMarch 4, 2022\n\n22-HAFE4-WL-03\u002FCMS No. 619373\n\nThe United States Food and Drug Administration (FDA) inspected your facility located at 1864 NW 22 St., Miami, FL 33142 from August 31, 2021 to September 14, 2021. Your facility manufactures food products including liquid flavors, marshmallow powder, and ice cream stabilizer. Our inspection focused on liquid food flavors and found serious violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP & PC rule), Title 21, Code of Federal Regulations (CFR), part 117 (21 CFR part 117). At the conclusion of the inspection, FDA issued an FDA Form 483, Inspectional Observations, listing the deviations found at your facility.\n\nBased on FDA’s inspectional findings, we determined that you did not follow the requirements of the CGMP & PC rule. The failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of the CGMP & PC rule (located in subparts A, C, D, E, F, and G of part 117) is prohibited by section 301(uu) of the Act (21 U.S.C. § 331(uu)). Further, during the inspection, you revised your labels to include the allergens and colors used in the production of many of your products; however, several of your products with revised labels (i.e., Medina brand Vanilla Flavor Imitation (White), Artificial Flavor Mantecado, and Marsh-Mallow No. 2 Meringue) remain misbranded within the meaning of section 403 of the Act (21 U.S.C. § 343). You may find the Act and further information about the CGMP & PC rule through links in FDA's home page at http:\u002F\u002Fwww.fda.gov.\n\nWe received your firm’s written response to the FDA Form 483 dated September 24, 2021, which included a description of your corrective actions taken and planned. After reviewing the inspectional findings and your response to the observations listed in the FDA Form 483, we are issuing this letter to advise you of FDA’s concerns and provide detailed information describing the findings at your facility. We address your response below.\n\nPreventive Controls (21 CFR part 117, Subpart C)\n\nYou did not identify and evaluate undeclared allergens due to an incorrect label as a known or reasonably foreseeable hazard to determine whether the hazard requires a preventive control in your allergen-containing liquid food flavors, as required by 21 CFR 117.130(a)(1). Specifically, your hazard analysis for “(b)(4)” did not consider undeclared allergens, but your Vanilla Flavor Imitation (White) and Chocolate Flavor both contain egg (a major food allergen). Foods containing allergens can cause serious adverse health consequences or death to allergic individuals if they consume a food to which they are allergic. A knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify food allergens as hazards requiring a preventive control. Preventive controls for food allergens include procedures, practices, and processes employed for labeling to ensure that all food allergens are included on the label (see 21 CFR 117.135(c)(2)(ii)). You did not have such controls in place as evidenced by your September 9, 2021, recall of your Vanilla Flavor Imitation (White) and Chocolate Flavor products, due in part to undeclared egg. The deficiency was revealed when FDA investigators observed that your Mantecado Flavor contains sugar yolks, which contain egg. Your Mantecado Flavor is used as an ingredient in your Chocolate Flavor, which is used as an ingredient in your Vanilla Flavor Imitation (White). However, until the FDA inspection, you were not declaring the egg allergen on product labels for Vanilla Flavor Imitation (White) or Chocolate Flavor.\n\nIn your written response, you stated that your labels for the Vanilla Flavor Imitation (White) and Chocolate Flavor will be updated to include allergens and promised to complete a label review and document the label review for any future products made to ensure compliance. We will review the adequacy of your labeling corrective actions during the next inspection. Your written response did not include a revised hazard analysis or new preventive control procedure to ensure control of the undeclared allergen hazard.\n\nMisbranding\n\n1. Your Medina brand Marsh-Mallow No. 2 Meringue product is misbranded within the meaning of section 403(f) of the Act [21 U.S.C. §343(f)] because the label contains statements in Spanish but does not contain an ingredient statement and “contains” statement in Spanish, as required by 21 CFR 101.15(c)(2). Further, your Artificial Flavor Mantecado product is misbranded within the meaning of section 403(f) of the Act because it does not contain a statement of identity in English, as required by 21 CFR 101.15(c)(1).\n\n2. Your Medina brand Vanilla Flavor Imitation (White), Artificial Flavor Mantecado, and Marsh-Mallow No. 2 Meringue products are misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] in that the products are fabricated from two or more ingredients and the common or usual name of each ingredient is not declared on the label, as required by 21 CFR 101.4. Specifically:\n\na. “Vegetable Gum” and “Gum” are not the common or usual names for these ingredients. We note that the flavor formulations include Xanthan gum and Tragacanth gum; however, the ingredient lists declare “vegetable gum.” There is no provision in 21 CFR 101.4(b) for the generic term “vegetable gum,” nor for the collective listing of gum ingredients. For the Marsh-Mallow No. 2 Meringue product, we note that the ingredient list declares “Tragacanth, Gum”; it is unclear whether this is a typographical error with a misplaced comma or is intended to refer to two ingredients.\n\nb. The labels fail to list some of the ingredients in the formulations. For example, based on the formulations provided, the Medina brand Vanilla Flavor Imitation (White) contains sugar and honey and the Mantecado formulation contains sugar; however, these ingredients are not declared in the respective ingredient lists.\n\nc. The formulations for both flavor products (Medina brand Vanilla Flavor Imitation (White) and the Artificial Flavor Mantecado) include the ingredient “Benzo dihydro pyrone dolcotone.” Based on the photo of the label of this ingredient, the name is Benzodihydropyrone. The Mantecado label declares the ingredient as “dolocotone” and the Vanilla flavor does not declare this specific ingredient. Additional names for this ingredient are found here: https:\u002F\u002Fwww.cfsanappsexternal.fda.gov\u002Fscripts\u002Ffdcc\u002Findex.cfm?set=FoodSubstances&id=DIHYDROCOUMARIN. “Dolocotone” is not an appropriate common or usual name for an ingredient.\n\nd. The formulation for the Marsh-Mallow No. 2 Meringue includes the ingredient “Clearjel,” which is modified corn starch; however, the ingredient label declares “starch,” which is not the appropriate common or usual name for modified corn starch.\n\ne. The ingredients on the Marsh-Mallow No. 2 Meringue label are not declared in descending order of predominance based on the formulation. For example, according to your (b)(4) record, the amount of salt used in the product is “(b)(4)” of a bag which weighs (b)(4) pounds, resulting in (b)(4) pounds of salt. Your product label lists salt after ingredients such as Ethyl Vanillin and Vanillin which are less than (b)(4) pounds each in the formulation.\n\n3. Your Artificial Flavor Mantecado product is misbranded within the meaning of section 403(e)(2) of the Act [21 U.S.C. §343(e)(2)] because it fails to bear an accurate statement of the net quantity of contents in terms of weight, measure, or numerical count as required by 21 CFR 101.7. The label includes two different net quantity declarations, “(b)(4)” and below that, “(b)(4)”. The net quantity of contents must be accurate; therefore, a label cannot declare two different net quantities.\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure your facility complies with all requirements of federal law, including FDA regulations. You should take prompt action to correct or implement corrections to the violations cited in this letter. Failure to do so may result in legal action without further notice, including, without limitation, seizure, injunction, or administrative action for suspension of food facility registration if criteria and conditions warrant.\n\nAdditional comments:\n\nWe note that “Vanillin” is misspelled as “Vainillin” twice on the Mantecado label. We also note that “Latose” on the Marsh-Mallow No. 2 Meringue label likely is intended to refer to “Lactose.”\n\nPlease notify FDA in writing, within 15 working days of the receipt of this letter, of the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration. If you cannot complete addressing these violations within 15 working days, state the reason for the delay and the timeframe within which you will do so.\n\nPlease send your reply to the Food and Drug Administration, attention of: Mr. Ramon A. Hernandez, Program Division Director, 466 Fernandez Juncos Avenue, San Juan, Puerto Rico 00901. If you have questions regarding this letter, please contact Mr. Donald J. Mee, Compliance Officer, at (904) 353-4560 Ext. 114, or via e-mail at donald.mee@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nRamon A. Hernandez\n\nDistrict Director, San Juan District Office\n\nProgram Division Director,\n\nOffice of Human and Animal Food Operations\n\nDivision IV East","Medina Baking and Powder Products, Inc.","medina-baking-and-powder-products-inc-619373-03042022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedina-baking-and-powder-products-inc-619373-03042022","2026-10-26T08:09:23.108968+00:00","2022-03-29","619373","Food & Beverages","2024-01-12","Mr. Roberto Martin","2026-08-20T02:04:27.277+00:00","Electronic Mail","2022-03-04",8,{"510k":174,"classification":175,"enforcement":176,"event":177,"event_backfill":178,"pma":179,"warning_letter":180},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]